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Abstract 
This thesis discusses the synthesis and structural analysis of 
molecules pertinent to current problems in the areas of biosynthesis, 
structure activity relationships and cell biology. 
Chapter one investigates the structure of an N-terminal blocked 
derivative of methionine 5enkephalin, in DMSO solution, using single and 
two dimensional nmr techniques. Analysis of the data using standard 
methods indicates the formation of a type I' beta turn centetec around 
the two glycine residues. 
Chapter two deals with the development and optimisation of a 
synthesis of D,L tyrosine which is suitable for the incorporation of isotopic 
labels to give enriched species such as [2- 13C, 15N]tyrosine which is a 
potentially useful biosynthetic probe. Possible uses of the probe are 
discussed and three routes are described. The most successful route is 
based on a modification of the Strecker reaction. 
Chapter three describes the synthesis, purification and 
conformational analysis of a fifteen residue peptide corresponding to the 
signal sequence of the hemagglutinin protein of the influenza virus 
A/WSN/33, the portion of the polypeptide responsible for its targeting to 
the cell surface. Circular dichroism studies of this N-terminal peptide in 
various solvents indicate that the peptide forms a predominantly p-sheet 
structure in aqueous solution and in alcoholic solutions of low 
hydrophobicity, while preferentially adopting a helical structure in more 
lipophilic solvent systems. The relevence of this to targeting to the cell 
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dmso dimethyl suiphoxide 
Dpp diphenylphosphinyl 
E. coli Escherichia coli 
El 	electron impact 
ER 	endoplasmic reticulum 
EtOAc ethyl acetate 
FAB 	fast atom bombardment 
Fmoc 9-fluorenylmethoxycarbonyl 
GF Greenfield and Fasman 
GPI guinea-pig ileum 
HA hemagglutimn 
HFLP 1,1,1,3,3 ,3-hexafluoroisopropanol 
HOBt 1-hydroxybenzotriazole 
HPLC high performance liquid chromatography 
LAB 	lithium aluminium hydride 
M 	multiplet 
Me 	methyl 
mRNA messenger RNA 
MS 	mass spectrometry 
NA 	neuramimdase 
nmr 	nuclear magnetic resonance 
nOe 	nuclear Overhauser effect 
NOESY nOe spectroscopy 
POMC pro-opiomelanocortin 
q 	quartet 
RNA 	ribonucleic acid 
ROESY rotating frame NOESY 
S 	 singlet 
SDS 	sodium dodecylsuiphate 
SPPS solid phase peptide synthesis 
SRP 	signal recognition particle 
SPRP signal recognition particle receptor 
t 	triplet 
t-Bu 	tertiary butyl 
TFA 	trifluoroacetic acid 
TFE 	trifluoroethanol 
TGN 	trans-reticular network 
TOCSY total correlation spectroscopy 
TRNOE transfered NOE 
UV 	ultra violet 
vRNA viral RNA 
Amino Acid Side Chain 3-Letter Code 
Alanine CH3 Ala 
Argrnine (CH2)3NHC(NH)NH 2 Arg 
Asparagine CH2CONH2 Asn 
Aspartic Acid CH2COOH Asp 
Cysteine CH2SH Cys 
Giutamic Acid (CH2)2COOH Glu 
Glutamine (CH2)2CONH2 Gin 
Glycine H Gly 
Histidine CH2(im) 1 His 
Isoleucine CH(CH3)C2H5  Ile 
Leucine CH2CH(CH3)2 Leu 
Lysine (CH2)4NH2 Lys 
Methionine (CH2)2SCH3 Met 
Phenylalanine CH2C6H5 Phe 
Proline2 Pro 
Serine CH20H Ser 
Threomne CH(OH)CH3 Thr 
Tryptophan CH2(ind)3 Trp 
Tyrosine CH2C6H40H Tyr 
Vaiine CH(CH3)2  Val 
Notes: 
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The opiates have long held a particular fascination for scientists 
and laymen alike. This reflects the unique therapeutic value of these 
agents, the mystery surrounding their mode of action and the devastating 
effects wrought by opiate abuse. The narcotic analgesics produce a wide 
spectrum of pharmacological effects, which may vary from species to 
species, and present a bewildering picture to the observer. For many years 
the uncertainties surrounding the mechanism of opiate action attracted a 
great deal of interest but it was not until the early 1970's that the opiate 
receptor became a defined pharmacological entity'. 
An added impetus to narcotic research was given by two separate 
but related developments in in vitro analysis. Firstly, the development of 
the guinea-pig ileum (GPI) as a model for opiate action 2 and the discovery 
of the mouse vas deferens as a second model of opiate action 3. Secondly, it 
became possible to demonstrate directly the existence of pharmacologically 
relevant, opiate receptor binding sites in the brain and gut 4 '5& It was 
therefore possible to define opiate action in strict pharmacological terms 
at both the cellular and molecular level. 
In view of the discovery of the morphine receptor it was proposed 
that morphine (1) might be analogous to other plant alkaloids like 
nicotine (2) or muscimol (3) which mimic the action of endogenous 
neurochemicals such as acetylcholine (4) and y-aminobutyric acid (5)78• 
This triggered off the search for an endogenous ligand for the opiate 
receptor. Evidence for such a compound was obtained when an unknown 














to morphine9"0 . The unknown factor was soon characterised as a mixture 
of low molecular weight peptides" and mass spectra of the acylated and 
methylated derivatives were initially used to sequence the peptides 
showing them to be Leu5-enkephalin (6) and Met5-enkephalin (7)12. 
Independent confirmation of these sequences was later obtained by the 





With further study it soon became apparent that the concept of one 
opiate receptor and one or two ligands was an oversimplification. This was 
made evident with the discovery of the 91 amino acid polypeptide 3-
lipotropin'4"5 , which in itself was inactive, and a number of peptides 
corresponding to portions of its C-terminal region namely a,P and y 
endorphin, (8), (9) and (10), which did possesses opiate like properties. This 
was followed by the identification of dynorphin (11)16  as the active factor 
of a pituitary extract. While (11) possess opiate receptor activity its 
properties are significantly different from the enkephalins. 
1.2 Biogenesis 
The explosion of interest in the endogenous opioid peptides in the 
mid to late seventies resulted in the extensive characterisation of the 
opioid peptides, thus providing a valuable model system for the 
investigation .of general features such as biosynthesis. 
Peptide hormones are in general derived from the enzymic cleavage 
of larger, and generally inactive, prohormones which are synthesised on 
membrane bound ribosomes. The cleavage of the signal sequence on entry 
to the endoplasmic reticulum yields the prohormone which is sequentially 
cleaved, yielding one or more biologically active peptides that are 
available for secretion. In the case of cellularly secreted hormones, 
cleavage appears to follow an ordered pattern and initially involves 
proteolytic attack at paired basic amino acid sequences. Attack at the 
carboxy terminus of the basic amino acids leaves the active peptide with a 
basic amino acid on the C-terminus which is subsequently removed by a 
carboxypeptidase B like enzyme to give the active peptide 17 . 
It was originally thought that -lipotropin was a precursor of Met 5-
enkephalin as its N-terminal sequence corresponds to the primary 
structure Met5-enkephalin'8 . This is however highly unlikely; apart from 
not explaining the origin of Leu 5-enkephalin, the Thr-Ser sequence which 
links the Met5-enkephalin sequence to the rest of 3-lipotropin would be a 
very unusual cleavage site for the production of the pentapeptide. It 
should also be noted that 3-endorphin and the enkephalins are not found 
in the same organs. The enkephalins have been found in the posterior 
lobe of the pituitary whereas -endorphins have been found only in the 
anterior and intermediate lobes of the pituitary 19 , and tissues such as the 
striatum and adrenal medulla have been found to contain the enkephalins 
but no -endorphin 20 '21 . However for conclusive evidence that 3-lipotropin 
is not involved in the biosynthetic pathway of enkephalins it would be 
necessary to isolate a precursor containing the enkephalins' sequences. 
The work undertaken in attempting to elucidate the origin of the 
opioid peptides has been the subject of various review articles' 23 . It is 
now clear that there are three separate families of endogenous peptide 
opiate receptor ligands: enkephalins, endorphins and dynorphins. They 
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are derived from three different prohormones: proenkephalin pro-
opiomelanocortin and prodynorphin, which are coded by mRNA's derived 
from three separate genes, fig 1.1. 
Dynorphin A 
Beta-neo-endorphin 	 Dynorphin B 





GENES > mRNA ) PRO-OPIOMELANOCORTIN 
Beta-lipotropin 
mRNA 	 Beta-endorphin 
PRO-ENKEPHALIN 
47/I \ Met5-enkephalin / / \ "\, 	Peptide E 
Leu5-enkephahn 	 Peptide F 
Met5-enkephalin-Arg-Phe 
Met5-enkephalin-Arg-Gly-Leu 
Fig. 1.1 Opioid peptides and their precursors 
The precursor of both natural enkephalins known as 
proenkephalin A, contains the amino acid sequences of both Met 5 and 
Leu5-enkephalin in a fixed ratio of six to one respectively, although some 
of the Met5-enkephalin sequences incorporate several more amino acids to 
produce 	larger, 	C-terminally 	extended, 	opioids. 	Pro- 
5 
opiomelanocortin(POMC) is the common precursor of the opioid 1 3-
endorphin and although this contains a Met 5-enkephalin sequence at its 
amino terminus no Met 5-enkephalin is derived from POMC. 
Prodynorphin, also known as proenkephalin B, contains Leu 5-enkephalin 
sequences but no Met5-enkephalin sequences. The opioid peptides derived 
from this precursor include the dynorphins, 13-neodynorphin and 
leumorphin, all of which contain the Leu 5-enkephalin sequence at their 
amino terminus. There is evidence to suggest that Leu 5-enkephalin is also 
derived from proenkephalin B. This is feasible in light of the fact that in 
the dynorphins the Leu 5-enkephalin sequence is followed by two arginine 
residues, which would facilitate enzymatic cleavage, and the distribution 
of the dynorphins and enkephalins is often contiguous. 
The identification of proenkephalin and prodynorphin would 
appear to have solved the problem of the biosynthesis of brain 
enkephalins. Moreover the existence of Leu 5-enkephalin in two separate 
precursors would neatly explain how the ratio of Leu 5 and Met5-
enkephalin can vary in different regions of the brain. 
LI] 	Ii iii i 
The concept that there are several types of opioid receptors was 
originally derived from the observation that in man nalorphine(12) had a 
dual action, antagonising the analgesic effect of morphine and also acting 
as an analgesic in its own right. It has been suggested that the analgesic 
effect of nalorphine is mediated by a receptor which is different from the 
morphine, j.L-receptor, and has been referred to as the K-receptor. 
When the enkephalins were first discovered it was assumed that 
they adopted a conformation analogous to that of morphine, with a rigid 
51 
structure, however it was noted that some alkaloid opiates could not 
displace [3HTyr1,Met5]enkephalin (13) from its receptor efficiently and 
the enkephalins could not compete for alkaloid binding sites 28 . While it 
has been proposed that this is due to different modes of binding to the 
same receptor or conformational changes at the receptor induced on the 
enkephalins26 , later work has suggested that these binding phenomena 
are due to the existence of multiple classes of opiate receptor with 
differing affinities for various opiates 27 '28 . 
From the results of various bioassays and radioreceptor assay 
studies the alkaloid opiates have been found to be more potent in the GPI 
test than the enkephalins whereas the reverse is true for the vas deferens 
assay. These observations indicated that the opioid peptides interact 
with two types of receptor : the p-receptor, with which morphine 
preferentially interacts, appeared to predominate in the guinea-pig ileum, 
whereas a 8-receptor, which is different from the p or K receptor and with 
which the enkephalins interact preferentially, appeared to predominant 
in the mouse vas deferens 30 . 
Work done on the selectivity of the opiate peptides towards the 
three receptor subtypes have shown the enkephalins to have selectivity 
for the s-receptor. Most of the products of prodynorphin interact with 1C-
receptors while all three families of opioid peptides have affinity for the p-
receptor23 '31 . 
The three classes of opiate binding sites are now firmly recognised. 
Although there is some recent evidence for the existence of subdivisions of 
the K and p sites28, no firm evidence for further subdivisions of receptor 
types has been shown. 
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In order to design super-agonists a great deal of structure activity 
work has been done on the enkephalins, with the aim of identifying the 
essential functionalities required for receptor site binding. Early work 
showed that the blocking of the C-terminal either by dansylation or 
amidation resulted in analogs with equal potency 32. Blocking of the N-
terminus generally resulted in analogues with less activityS 3,34 but some 
alkylated and acylated analogs were found to be active as were analogs 
with additional amino-acid residues attached to the N-terminus. 
Replacement of L-Tyr 1 with D-Tyr or with other amino acids' 37 results 
in a dramatic loss of activity as does derivitisation of the phenolic 
hydroxyl 32'. These results suggest that an intact L-tyrosine moiety in 
position one is essential for activity. 
Early work demonstrated that the enkephalins were subject to 
rapid deactivation when exposed to tissue homogenates and purified 
enzyme preparations such as carboxypeptidase-A and leucine 
aminopeptidase. In view of these results it was not surprising that in in 
vivo studies, even after central administration, the agonist activity of the 
enkephalins were at best transient. Examination of the degradation 
products by thin layer chromatography showed the deactivation of the 
enkephalins to take place principally through cleavage of the Tyr 1-G1y2 
amide bond yielding the inactive tetrapeptides (14) and (15). 
H.Gly.Gly.Phe.Met.OH 	H.Gly.Gly.Phe.Leu.OH 
(14) 	 (15) 
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In order to render the amide bond inaccessible to cleavage G1y 2 was 
replaced with D-alanine to give the analog (16), which was equipotent to 
Met5-enkephalin in receptor binding, assays but was not degraded. It also 
"'
/ 	C 414 e.'i-L 
showed analgesic activity when administered intracereboventrically. 
Further work on analogues substituted at the two position showed that 
replacement of G1y2  with D-Met or D-Ser produced even more potent 
analogues40. However analogues with L-amino acids other than glycine in 
position two had diminished activity41,42 . 
Position three was initially shown to be less tolerant towards N- or 
C- substitutions and replacement of Gly 3 with with alanine resulted in 
complete loss of activity 43. The presence of an aromatic functionality at 
position four was found to be essential for activity, though introduction of 
a nitro functionality in the para position of Phe 4 gave a compound with 
very high potency in the GPI assay. 
H.Tyr.DA1a.Gly.Phe.Leu.NH2 
(16) 
A wide variety of manipulations have been reported at the C-
terminus. It was found that an aliphatic residue in position five and an 
unmodified carboxy group at the C-terminus were required for efficient 
binding to the 8-receptor45 . On the other hand, interaction with the p-
receptor is not appreciably effected by structural modifications at the C-
terminal and omission of the fifth residue produces analogs with 
enhanced activity in the GPI assay4446 . 
Thus by the late seventies the minimum structural requirements 
for interaction with the opiate receptor were perceived as encompassing 
the elements of an intact L-Tyr 1 moiety and the aromatic nucleus of the 
Phe4 separated by an appropriate dipeptide spacer. However several 
interesting modifications of the enkephalin backbone performed in order 
to enhance the stability of the peptides towards enzymatic degradation 
showed that replacement of the Tyr-Gly amide bond with a CH 2-NH 
linkage, producing an analogue (ri) did not result in a drop in activity 47 . A 
similar replacement of the amide bond using an olefinic linkage produced 
an analogue (18) which had three times the potency of Leu 5-enkephalin 
methyl ester in the GPI assay48. However replacement of the Gly-Gly 
amide bond with a CH 2-NH bond results in complete loss of activity 47 . 
This showed that a peptide bond between Tyr 1 and G1y2 was not a 










The early view that a dipeptide spacer was essential for opiate 
activity was challenged with the discovery that 3-casomorphin (19) 49 and 
dermorphin (20) 0  both had opiate activity while having only a single 
amino acid residue between the two essential tyrosine and phenylalanine 
residues. With this in mind several analogs were synthesised including 
(21)' and (22)52 which were at least as potent as Met 5-enkephalin 
demonstrating that of the Phe 4 residue only the aromatic ring is 
necessary for interaction with the opiate receptor and an amide bond two - 
carbon atoms distant from the phenyl ring is unnecessary, as is an - 
amino acid in position three. 
Recent attempts to synthesise biologically active enkephalin 
analogs with minimal structure produced analogs (23)53 and (24) 4 . (23) 
efficiently inhibits morphine activity and the Leu 5-enkephalinamide 
analogue (24) is reported to be equipotent with the parent amide in the 
GPI assay. It is now generally accepted that the minimal structure 
neccessary for interaction with the opiate receptor is a basic nitrogen, a 
hydroxylated phenyl ring and a second phenyl ring fixed at appropriate 
points in space.fig. 1.2. 
OH 
Fig. 1.2. Minimal structural requirements for opiate activity 
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The most attractive rationalisation for the pharmacological activity 
of the enkephalins and their analogL;wisthat their receptor binding is 
similar to that of the morphine alkaloids. If this is the case it would be 
expected that the conformation adopted by the peptides at the receptor 
site would be topologically similar to that of the rigid morphine skeleton, 
and models of the enkephalins have been constructed on the basis of 
structural comparisons with the alkaloid opiates 55'. As a result a number 
of studies have been made of the conformational analysis of the 
endogenous opioid peptides in the search for information about their 
receptor-bound conformations. 
The problem is a difficult one because of the inherent flexibility of 
small peptide molecules many conformational states are possible, 
especially in solution. The situation is further complicated through the 
existance of various opioid receptor sub-classes that have different 
structural requirements. The enkephalins having significant affinity for 
both the .t and ö receptors and may bind to the two sub-classes by 
assuming two distinct conformations. Three main approaches have been 
used in the quest to determine the structure of the enkephalins, these 
being, crystal structure determination, nmr spectroscopy and theoretical 
energy calculations, each of which has been the subject of a number of 
reviews. 
WWiiiisii 
Mathematical analysis of the enkephalins have suggested a number 
of low energy conformations corresponding to different secondary 
structures. These include a type IF 3 bend centered around the G1y 3 and 
12 
Phe4 residues, first proposed by Isogai et al in an early investigation57 , 
which is stabilised by a hydrogen bond between the tyrosine hydroxyl and 
the carbonyl group of the G1y 3 residue. Similar structures have been 
proposed by other workers who have found a number of minimal energy 
conformations characterised by a turn around the Gly 3 and Phe4 residues, 
as well as low energy structures corresponding to turns around the G1y 2 
and G1y3 residues58 '59 . 
Other studies using the Monte-Carlo method to obtain statistical 
samples of conformations of Leu 5-enkephalin suggest a predominance of a 
local folded form in the zwitterionic state and mainly extended 
conformations in the cationic form 60 . Thus from theoretical calculations 
the enkephalins would appear to be able to access a number of low energy 
states and may well be present as a mixture of a number of different 
conformations. 
1.5.2 Crystal Structure Determination 
Crystal structure determination is generally accepted as being the 
definitive method of structure elucidation for rigid molecules. However in 
the case of conformationally flexible molecules the validity of 
crystallography as a definitive tool may be questioned for two reasons 
firstly the conformation exhibited in the solid state may be dominated by 
intermolecular forces which are not present in dilute solution in biological 
fluids, and secondly interaction with a receptor site may stabilise 
conformations different from those imposed by crystal packing restraints. 
The first X-ray structure of Leu 5-enkephalin, published by Smith 
and Griffin60 demonstrated the presence of a type 10 turn centered on the 
two glycine residues and stabilised by two intramolecular hydrogen bonds, 
13 
one between the amino group of Tyr 1 and the carbonyl oxygen of Phe 4 and 
the second between the amide proton of Phe 4 and and the Tyr 1 carbonyl. 
A similar structure containing a type I' 13 bend was also found for the 
Leu5-enkephalin analog [(4'Br)Phe 4,Leu5]enkephalin62 in the solid state. 
However, in marked contrast to the folded conformations observed in the 
above studies, a separate study showed crystals of Leu 5-enkephalin to 
contain molecules with extended backbones in the form of an antiparallel 
13-sheet63 . 
Only one crystal structure has been published for a Met 5-
enkephalin derivative that being the brominated analog - 
[(4'Br)Phe4,Met5]enkephalin64. This was found to adopt a dimeric 
structure in the form of an antiparallel 13-pleated sheet. 
The occurence of two entirely different types of secondary structure 
in the solid state is indicative of the flexibility of the enkephalin molecules 
and is consistent with the the results of the theoretical studies which 
postulated that the low energy conformers of the enkephalins would 
encompass both extended and folded forms. 
1.5.3 Nuclear Magnetic Resonance Studies in Solution 
In the quest to determine the solution structure of the enkephalins 
proton nuclear magnetic resonance(nmr) has been the most extensively 
used technique, and the results of numerous studies have appeared in the 
literature65'63 . In common with the crystal structure determinations and 
with theoretical energy calculations the structures proposed fall into two 
distinct groups : those characterised by a 13-bend and those characterised 
by an anti-parallel 13-sheet. 
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The most frequently postulated structures are those characterised 
by 13-turns and these themselves fall into three distict classes. The first, a 
type I 13 turn centered on the G1y2 and G1y3 residues has been advanced 
for both the natural enkephalins end their truncation peptide 
H.Tyr.Gly.Gly.Phe.OH in both aqueous and dmso solutions67,,69.  A 
second class of structures, again characterised by a type I 13 turn in this 
case around the Gly2 and Gly3 residues, has been suggested for both Met 5 
and Leu5 enkephalin in dmso solution 70'71 . A third class of structure 
incorporating a different type of 13-turn has recently been reported by two 
groups. Milon et al recently carried out an elegant study on Leu 5-
enkephalin and its active analogs H.Tyr.(DAIa).Gly.Phe.Leu.OH and its 
corresponding N-terminal amide in a phospholipid environment 72. Using 
transferred nuclear Overhauser effects(TRNOE) to observe dipolar 
couplings evidence was produced which was indicative of a monomeric 
structure involving a typell' f3 bend centered on the Gly 3 and Phe4 
residues accompanied by a y  turn around the amino acid in the two 
position. This was supported by the evidence for a type II f3 bend 
postulated for Leu 5 enkephalin in dmso solution on the basis of ROE 
measurements73 . 
A structure characterised by an antiparallel 13 sheet has been 
proposed to exist for both natural enkephalins in high concentrations in 
dmso solutions but not in aqueous solution 71 '74 . 
Nuclei other than hydrogen have been used to a lesser extent in 
investigations of enkephalin secondary structure. Experiments carried out 
using 'C nmr favour a type I 13 turn arouJ the Gly3 and Phe4 residues on 
the basis of torsion angles calculated from coupling constant data 75'76 . A 
study using the 15N enriched tetrapeptide H.Tyr.Gly.Gly.Phe.OH in dmso 
15 
concluded that the peptide was only present in a folded confbrnvation 
when in the zwitterionic form but adopted extended conformations at high 
and low pH77. 170 nmr has been used in an attempt to elucidate the 
differences in the hydrogen bonding at G1y 2 and G1y3, however the study 
was limited to a fully protected Leu 5-enkephalin and failed to produce any 
evidence for hydrogen bonding involving the carbonyl oxygen of these two 
residues78 . 
1.6 Discussion 
In view of the conformational flexibility inherent in the structure of 
the enkephalins the crystal structures determined for these molecules, 
dominated as they are by intermolecular forces, may be of little relevance 
to the conformation adopted on binding to membrane bound receptors. 
Earlier nmr studies on Met5-enkephalin have been on the whole based on 
single dimensional spectra which were in some instances obtained in 
solutions of high concentration, a condition which it is now acknowledged 
can give rise to dimerisation. Because of the conflicting evidence in the 
literature we decided to reinvestigate the solution structure of Met 5-
enkephalin in dilute solution using 2D nmr techniques. 
In this work we chose to study Dpp.Met 5-enkephalin an N-terminal 
blocked derivative of Met 5-enkephalin. This derivative was chosen for two 
reasons. Firstly functionalisation of the N terminal amine, with the 
diphenylphosphinyl group 79 , inhibits the formation of dimers by denying 
amine carboxylate ionic interactions. Secondly, by employing a bulky 
hydrophobic group we hoped to stabilise a single conformation. As 
discussed previously, derivofisation of the amino terminus does not 
necessarily lead to loss of activity. 
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The large number of protons present even in relatively small 
peptides leads to very complicated nmr spectra. In order to assign the data 
obtained it is necessary to use two dimensional techniques which both 
resolve the information and provide additional aids to its assignment. 
Examples of the typical information which can be obtained using 2D nmr 
spectroscopy are shown in fig. 1.3. 
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Fig 1.3 Information available from 2D nmr 
The method of choice for obtaining evidence of secondary structure 
in peptides or proteins in solution is the detection of the nuclear 







-- - , ; 
---14 	 • 0 
	 4.0 
- ------- —e 
II 
	 I 	I 5.0 
I II 




II I 	 7.0 
I 	' 







9.0 	8.0 	7.0 	6.0 	5.0 	4.0 	3.0 	ZA 
P Ph 
Fig. 1.4 2D COSY spectra of Dpp.Met5enkephakin in dmso d6 at 273K. 
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( less then 3.5-4.OA ) interproton distances. Unfortunately for small 
peptides in the commonly used frequency range, 300-600MHz, the nOe 
values are frequently close to zero 80. However a method for measuring 
nOe's in the rotating frame, the rotating frame nuclear Overhauser 
effect(ROE) 80 '81 gives ROE values which are always positive even for small 
peptides and is thus invaluable for the qualitative evaluation of through 
space proton-proton interactions in molecules such as the enkephalins. 
We therefore chose to use the two dimensional ROESY 8 ' procedure for the 
study of Dpp.Met5-enkephalin. 
1.6.2 Assignment of the Proton Spectra 
Assignment of the proton chemical shifts was performed using 2D 
COSY and ROESY experiments using the methods described by 
Wuthrich82 . The assignment protocol for the Gly 3, Phe4 and Met5 residues 
shown in figure 1.4 illustrate the identification of the spin systems 
corresponding to the individual amino acids. 
The sequential assignment of the Gly2 and Gly3 resonances follow 
from consideration of the cross peaks observed on the ROESY spectrum. 
The two glycine residues show characteristic NH triplets at 8.56 and 8.73 
ppm. The higher field amide NH resonance shows a cross peak with the 
CaH of Tyr 1 at 3.14 ppm and no such connectivity is observed for the Gly 
NH at 8.73 ppm. This unambiguously assigns the NH at 8.56 ppm to G1y2 , 
and consequently the one at 8.73 ppm to Gly 3, thus discriminating 
between the two spin systems. 
The chemical shifts and coupling constants are tabulated (tables 1.1 
and 1.2). 
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Residue Ha H13 NH Other 
Tyr 1 3.41 2.90,2.88 5.87 7.06,6.78 
G1y2 3.71,3.80 8.56 
G!y3 3.65,3.75 8.73 
Phe4 4.54 3.03,2.81 7.87 
Met5 4.21 1.98 8.26 2.45,2.03 
Table 1.1 Proton chemical shifts(ppm) for Dpp.Met 5-enkaphalin 
in dmso-d6 at 28°C 
Residue 2jalbM 3J c3 3jpl 02 3 NHCHcX 
Tyr1 a a 8.2 
G1y2 17.2 5.8,5.8 
G1y3 -17.3 5.8,5.8 
Phe4 4.7,9.0 13.7 7.7 
Met5 --- a 8.5 
Table 1.2 Coupling constants(Hz) for Dpp.Met 5-enkephalin 
a=not obtainable from spectrum 
1.6.3 Identificaton of p 13 Turn 
With regard to the application of nmr data to the identification of 
secondary structural features in peptides there are two principle criteria 
for the selection of "useful" proton-proton distances. In the first case they 
Tyr 1 G1y2 - 	 G1y3 Phe' Met5 
3N .N(i,2)  
3(i,i+1)  
Table 1.3 Important Dipolar couplings in the ROESY spectrum of 
Dpp.Met5 enkephalin. 
ORRADATED SIGNAL RESPONSE 
Tyr1 NH Dpp aromatics 












Phe413 Phe4 aromatics 
Met5NH PheCaH* 
MetCaH 
Table 1.4 n.O.e results. All responses were less than 1% except for * 
which was 3%. 
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should be significantly short so as to give rise to observable interactions in 
ROESY or NOESY experiments, ie shorter than 4A. The second and most 
important criterion is that the proton-proton interactions should be 
characteristic for different secondary structures. 
A summary of the important dipolar couplings found in the ROESY 
experiment on DppMet 5-enkephalin is shown in table 1.3. The integrity of 
the dipolar couplings was confirmed by a series of nOe difference 
experiments which are summarised in table 1.4. In this case the ROE's 
with greatest diagnostic value are those between the NH's of G1y 2 and 
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These are indicative of a local folded 0 turn structure and can be 
used to discriminate between the various types of 0 turn. For turns of 
type I the shortest proton-proton distances are those between NHi and 
NH 1 and between NH 1 and N}jj 2  which are of the order of <2.5A. For 
turns of type II the shortest distances are those between CaHi and NH 1 
and NH 1 and NH 2 fig. 1.6. 
Fig. 1.6 Standard type I and type II turns showing the 
1H- 1H contacts of interest for the identification of (3-turns 
2]. 
The distinction between the pair in this case relies on the presence 
(type I) or the absence (type II) of a dipolar coupling between NHi and 
NHi+l, since in a type II structure the distance between these two protons 
increases to 4.5A which is insufficient to give rise to a strong ROE 
interaction. Thus the presence of a ROE interaction between the NH's of 
G1y2 and G1y3 differentiates between the two types, indicating that in our 
solvent system Dpp.Met5-enkephalin contains a conformer with a type I or 
type I' P turn centered on the Gly 2 and G1y3 residues. 
1.6.4 Counling Constants 
Analysis of the coupling constants between interacting nuclei yields 
information of the spatial orientation of the participating atoms. Owing 
to their ease of observation proton-proton coupling constants have a 
prominant position in the conformational analysis of peptides. The most 
useful are the vicinal NHCaH and H-CaC-H coupling constants which 
give the 4  and  x torsion angles and the geminal H-Ca-H coupling 
constants which give information on the 4'  and ii torsion angles of glycine 
containing peptides. The important torsion angles present in peptide 





Fig. 1.7 A peptide fragment showing the torsion angles 4, N' 0, and 
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The vicinal HNCaH2 couplings of the glycine residue give rise to an 
ABX spectrum. In this case the triplet splitting of the NH signal does not 
enable direct evaluation Of the 3j NHc.H  constant84. However the spacing 
between the outer components of the amide signal is equal to the sum of 
the JAx and BX  coupling constants and this has been shown to be related 
to the torsion angle 4) by the following relationship:- 
X3Jjmcaji) = -9.4cos24) - 1.1cos4) + 14.9 
For the coupling constants observed this gives a number of possible 
values for 4),  -65, -125, 65 and 125°. The 0 values required for a type I and 
type 110 turn are almost identical, ±600  for the first residue of the turn 
and ±90 or ±80° for the second residue of a type I and type II turn 
respectively82 . While an angle of ±60° is easily accomodated by the 
experimentally observed couplings a value in the region of ±90 0 would 
seem to be outwith the experimentally derived torsion angles. In any 
event the vicinal NHCaH2 coupling constant would appear to be of limited 
value in differentiating between .the two families of n-turn which differ 
only by 100  in the 4)  torsion angle of the second residue of the turn. 
The , torsion angle around the carbonyl-CaH bond provides a more 
definitive indication of the type of turn present. For both types of 13  turn 
the xV angle for the second residue is 0°, however for the first residue the XY 
torsion angle is markedly different for each type of turn ±30° for a type I 
turn and ±120' for a type II turn 82 . 
The geminal H-Ca-H coupling constant observed in nmr spectra of 
glycyl containing peptides is dependant on the xV angle but is independant 
of the torsion angle 4). 
In the spectra of Dpp.Met 5-enkephalin the geminal couplings of the 
methylene protons of the two glycine residues are 17.2 and 17.3 Hz for 
\ / 	 / 
N C 
Fig. 1.8 The dihedral angle 0 
Residue 0 T o 
Tyr1 0,153 
G1y2 ±60,±125 0,180 
G1y3  ±60,±125 0,180 
Phe4 0,150 
Met5 0,155 
Table 1.5 Torsion angles. 
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G1y2 and G1y3  respectively and are apparently negative in common with 
those of other tetrahedral carbon atoms. 
The most widely used model for the dependance of the glycine 
geminal coupling constant on the v torsion angle is that described by 
Cookson. According to this model geminal couplings of -17.2 and -17.3 
Hz correspond to angles of 00 or 180°(±40°) for the principle torsion angle 
V. 
To accomodate a type II turn a xV torsion angle of t120'  is required 
for the second glycine residue. This would correspond to a geminal 
coupling in the region of -13 to -15 Hz which is obviously excluded by the 
experimentally observed values. x V torsion angles of ±30° and 00  required 
for a type I or I' 13  turn are however easily accomodated by coupling 
constants in the region of 17Hz. This rules out the presence of a type II or 
II' 13 turn and provides further evidence supporting the presence of a type I 
or I' 13 turn in this molecule. However it should be noted that the torsion 
angles determined on the basis of nmr data do not allow discrimination 
between a type I and type I' 13 turn. 
The torsion angle e, fig. 1.8, corresponding to the angles between 
the amide NH and the CaH bonds for the tyrosine, phenylalanine and 
methioriine residues were calculated from their respective CaHNH 
coupling constants according to the method of BystrovM and are reported 
in table, 1.5 along with the torsion angles calculated for the glycine 
residues. 
The averaged conformational states of peptide side chains can be 
determined from the vicinal H-CaC13-H proton-proton coupling constants 
using the modified Karplus-type equations described by Feeney 87 and 
Pachler. These enable evaluation of the conformational states of the 
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amino acid side chains of peptides in terms of their distribution among the 
three different rotational states where X  equals -60, 60 and 1800  (tg, gg 
and tg respectively. 
Applying the criteria described by Pachier to the Phe 4 and Met5 
CaHCI3H coupling constants indicates a distribution of 77%tg and 23%gg 
for the Phe4 side chain and, 75%tg and 25%gg for the Met 5 side chain. 
While this method does not discriminate between the two possible trans-
gauche conformations, tg and tg -' Feeney's treatment does allow 
discrimination between these two forms although it in turn has the 
disadvantage of solving to two different sets of rotamer populations. 
However since only one set of solutions of the Feeney equation 
corresponds to the poulations obtained from Pachler's equations a 
combination of the two methods allows the complete solution of the 
rotamer population set. 
Application of this method gives the rotamer populations 63%tg, 
12%tg and 25%gg for the phenylalanine side chain and 69%tg, 2%tg 
and 29%gg for the methionine side chain. This indicates that both side 
chains favour the trans-gauche conformation. 
It was however impossible to calculate the rotamer populations of 
the tyrosine residue by this method due to couplings of the phosphorous 
atom to the CaH and C13H2  signals. 
1rnTh. 
The n-turn was used as a starting point for the model and was 
constructed using standard bond angles corresponding to type a I' 3 
turn82. The tyrosine spin system shows only two interresidue ROE's one 
between the tyrosine amide and G1y 2 amide protons and the second the 
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characteristic CaH,NH 1 dipolar coupling between the tyrosine Call and 
the G1y2NH. 
The H-NCa-H coupling constant of 8.2Hz corresponds to a 0 angle 
of 0 or 1800  and on the basis of modelling an angle of 00  seems more 
probable as an angle of 180 0 results in the diphenylphosphinyl group 
interfering with the 13-turn backbone. The tyrosine side chain is most 
easily accomodated in a transgauche+  conformation which is in accord 
with the observation of an ROE between the Tyr 1 NH and only one of the 
tyrosine 13 protons. Thus the conformation of the tyrosine residue with 
respect to the 13  turn can be defined as shown. 
(I 
The phenylalanine residue also seems to adopt a major 
conformation. A NHCcxH coupling constant of 7.7 Hz suggests a torsion 
angle 0 of 10 0 or 1500. From modelling an angle closer to a trans 
arrangement would appear to be the most acceptable as this is consistent 
with the observed ROE between one and only one of the phenylalanine 
methylene protons. This is in agreement with the trans gauche 
conformation derived from the CCCHCI3H coupling constants. 
The phenylalanine CaH shows a strong NOE (3.5%) with the 
methionine amide proton which is indicative of a parallel arrangement of 
the glycine CaR and the methionine NH bond. This fixes the Met relative 
to the Phe residue and hence to the 13  turn. 
The methionine side chain would appear to be well removed from 
the rest of the structure as no inter-residue ROE's are observed for the 
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methionine side chain protons and the only clues to its conformation are 
the strong NOE linking the the Phe 4 CaH proton to Met 5 amide proton, 
discussed above, and the predicted tg conformation of the side chain. A 
trans arrangement of the NHCcLH bond is again favoured from modelling 
as this reduces the steric interactions of the side chain with the rest of the 
structure. 
Using the above data and observations a model was constructed 
using the Alchemy II molecular modelling program. Figure 1.9 shows the 
integral P turn structure. The full structure, not including the hydrogen 
atoms is shown in figure 1.10. Fragments of the structure including the 
hydrogen atoms are shown in figures 1.11 and 1.12. 
The model constructed indicates clearly the position of the bulky 
Dpp group below the plane of the 3-turn, well removed from the rest of the 
structure. The tyrosine and methionine side chains extend outwards in 
the same plane as the 13  turn with the aromatic ring of the the 
phenylalanine residue adopting a more peripheral position. 
1.6.6 Energy Minimisation 
The model constructed from the nmr data was subjected to an 
energy minimisation procedure contained in the Alchemy II program. This 
produced a structure essentially the same as the one derived 
experimentally. Figure 1.13 shows the minimised structure minus the 
hydrogen atoms for clarity. The spatial arrangement of the amino acid 
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side chains and Dpp blocking group relative to the 0 turn are essentially 
those derived from the nmr data. Figures 1.14, 1.15 and 1.16 show the 
fragments of the minimised structure corresponding to those shown for 
the non-minimised structure. 
Fig. 1.9 The integral P turn of Dpp.Met 5 enkephalin 
Fig. 1.10 Backbone structure of Dpp.Met 5 enkephalin 
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Fig. 1. 11 Perspective view of the N-terminal portion of the .peptide 
Fig 1.12 Perspective view of the C-terminal region of the peptide 
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Fig. 1.13 Minimised structure 
Fig 1.14 Integral f3 turn of the minimised structure. 
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Fig. 1. 15 N-terminal portion of minimised structure 
Fig. 1. 16 C-terminal portion of the minimised structure. 
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1.6.7 Conclusion 
The initial choice of a type I' 3 turn in preference to a type I 3 turn 
would seem to be justified when considering the spatial requirements of 
the Dpp protecting group and the tyrosine side chain. While changing the 
3-turn from type I' to type I does not result in any conformational change 
at the carboxy terminus of the structure, i.e. the Phe 4 and Met5 residues, 
the N-terminus is considerably disrupted, resulting in the Dpp group 
impinging on the carboxy terminal region of the peptide. Thus a type I' 3 
turn structure is favoured on steric grounds. 
While the type I' turn described above is probably the dominant 
form in dmso solution the presence of other less populated folded and 
extended conformations cannot be ruled out. It is however clear that there 
exists a locally folded form containing a type I' P turn in dmso solution. It 
is tempting to speculate that this may be the conformation associated with 




For thousands of years man has utilized the pool of natural 
products for uses which have included medicines, poisons and recreational 
aids. Examples include opium, the air dried milky exudate from unripe 
fruit capsules of the opium poppy, of which morphine (25) is the major 
active constituent. This has been used since ancient times for its marked 
analgesic and narcotic effects. Salicin (26) found in extracts of willow 
bark, a source used for centuries in a variety of healing preparations for 
the treatment of fevers, was partly responsible for the synthesis of a more 
potent analogue acetyl salicyclic' acid or asprin (27). The toxic proprties of 
hemlock have been known since the times of the ancient Greeks, being 
reported as the source of poison used in the execution of Socrates 89 . The 









(27) 	 (28) 
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The seemingly infinite number of chemical species present in 
nature fascinated early chemists who could not rationally account for the 
production of such diverse and complex species and for many years it was 
thought that compounds present in living organisms contained some vital 
force. The realisation that natural products were formed by basically 
unexceptional chemical processes resulted from Wohlers "unexpected" 
preparation of urea, a well known constituent of urine, via the pyrolytic 
rearrangement of ammonium cyanate. 
As the structures of an increasing number of natural products 
became known, attempts were made to classify them in terms of 
structural type. It was therefore possible to spot characteristic structural 
features which suggested a particular precursor. Thus followed the total 
synthesis of natural products via hypothetical biosynthetic pathways 
which provided further evidence that biosynthesis proceded via standard 
chemical reactions without nature resorting to some "biological trickery". 
In addition the hypothetical intermediates of these biomimetic pathways 
were often found to be present in the organism containing the natural 
product under investigation. 
The real breakthrough in the determination of biosynthetic 
pathways came with the feeding of isotopically labelled precursors and the 
isolation of label containing natural products. Thus the direct 
incorporation of small molecules into natural products could be 
demonstrated. 
Incorporation of labelled precursors is normally effected in plants 
by feeding solutions to the appropriate tissue, or for micro-organisms by 
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their addition to the culture medium during the phase of maximum 
production of the required metabolite. Classical feeding studies involve 
feeding of 14c labelled precursors followed by isolation and systematic 
degradation of the resulting metabolite to determine the distribution of 
the labelling. 
More recently with the advent of nmr spectroscopy non-destructive 
methods of locating labelled atoms have been devised based on the 
recognition of suitably enriched isotopes, notably 13C, 15N, 2H and 17090 
Nmr spectroscopy offers many advantages over other available 
techniques when applied to biosynthetic problems. It is the only technique 
that can separately detect the presence of most biosynthetically useful 
elements and the only non-destructive method capable of determining the 
locations and concentrations of isotopic labels in a metabolite. 
Furthermore spin-spin coupling and isotope shift effects can be used to 
provide direct evidence for the incorporation of intact biogemc units and 
for the identification of processes involving bond formation and bond 
cleavage. Such information can only be deduced indirectly by other 
methods. 
The disadvantage of nmr is the quantities of labelled metabolite 
required for analysis, generally several milligrams, which may not always 
be available in some cases. This problem is not encountered when using 
radioisotopes due to the increased sensitivity of the detection techniques 
available. 
The problem of analysing small quantities of stable isotope labelled 
metabolite can be overcome using mass spectroscopy to determine the 
incorporation of labelled material. Identification of the position of 
enrichment being possible from the composition of the fragment ions. This 
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is however a much more labour intensive process and one in which the 
signal to noise is considerably reduced 91 . 
13C Labelling 
13C labelling is the most widely employed method for probing 
biological pathways and many reviews exist on the subject 92 ' 93'. The 
natural abundance of 13C  is 1.1% so providing the enrichment is 
significantly outwith the error of measurement ( about 0.5 - 1.0% 13C 
above natural abundance is usually sufficient ) feeding a singly labelled 
precursor allows direct identification of the enriched site from the 13C 
spectrum. 
When a precursor is labelled with 13C at two positions, which are 
spin-spin coupled, its fate can be determined by the absence or presence of 
this coupling in the metabolite. If coupling is preserved in the 13C 
spectrum of the labelled metabolite it is convincing evidence that part at 
least of the precursor is incorporated intact. Loss of the coupling 
accompanied by enrichment is proof of bond scission. 
Subsequently the use of amino acids enriched with 13c  and 15N in 
adjacent positions as probes have been used to effect in solving 
biosynthetic problems. a-Amino acids enriched at the 2-position with 13C 
and in the amino function with 15N offer significant potential as they 
possess in essence a labelled C-N bond the integrity of which can be 
detected by observing the one bond coupling, 1j,  in the 13C  or 15N nmr 
spectrum. This enables the characterisation of biochemical processes 
which can be conjectured to involve either conservation or cleavage of C-N 
bonds. 
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[2 13C, 15N]Glycine has been used to demonstrate that the carbon-
nitrogen unit of the 2-amino-3-hydroxycyclopent-2-enone moiety of the 
antibiotic asukamycin(29) is derived intact from glycine 95. Other examples 
of the use of [2 13C, 15N] labelled amino acids have appeared in the 
literature'97 . 
2.4 Tvrosine 
Many examples exist in the literature of biosynthetic pathways 
proposed to involve the incorporation of carbon-nitrogen units whose 
supposed origin is the 2C-N portion of tyrosine. 
2.4.1 CvcloDentvl Isocvpnides 
Cyclopentyl isocyanides such as trichovidrin (30), 3-(3'-
isocyanocyclopent-2-enylidene)propionic acid (31), and the epoxy acid (32) - 










The biosynthesis of (32) has been studied extensively and the 
proposed biosynthetic pathway is shown in scheme 2.1. This shows the 
formation of (32) via the oxidative cleavage of the tyrosine aromatic ring 
adjacent to the phenolic function at a or b followed by a cydisation process 
involving the carboxylic carbon atom and one of the two atoms originally 
meta to the phenolic function, depending on the initial cleavage site. 
HO \ '3 	
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The proposed ring cleavage and recyclisation accompanied by loss 
of a single carbon atom is in agreement with the observation of a loss of 
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one carbon atom on feeding [U 14C]tyrosine98 .99 , and with the retention of 
only two of the three contiguous carbon atoms of [3',4',5'- 13C3]tyrosine in 
the final product 99 . 
Feeding of [3- 1 C] and [1- 13 C] tyrosines produced (32) labelled in 
positions 5 and 7 respectively. This along with the observation that [1',2'-
13C2]tyrosine labels both side chain and ring functions in the final product 
indicates formation of the cyclopentene ring from the aliphatic portion of 
tyrosine and two of the carbon atoms of the aromatic ring, 1' and 2' or 1' 
and 6' depending on the initial cleavage site 99 . 
Although this gives a seemingly comprehensive account of the 
formation of (32) the biosynthetic origin of the isonitrile moiety remains 
unproven. Here is a case where [2- 13C, 15N]tyrosine would be a valuable 
probe. 
2.4.2 Thiamine 
Thiamine (33), also known as vitamin B 1 , is the precursor for the 
metabolically active thiamine pyrophosphate (34) which is the essential 
coenzyme involved in the enzymatic decarboxylation of cz—keto acids and 
in the transketolase reaction. 
Although much is known of the function of thiamine the 
biosynthesis of this compound remains largly undetermined. The 
enzymatic steps involved in the conversion of the pyrimidine and thiazole 
moietes to thiamine in yeast were elucidated some time ago 100 ' 101 , however 
the biosynthesis of the pyrimidine and thiazole moieties themselves are as 
yet undefined. 
The primary precursors of the pyrimidine unit differ in eukaryotes 
and prokaryotes. In prokaryotes the intermediacy of 5'- 
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aminoriboimidazoleribonucleotjde (5'-AIR) derived from formate and 
glycine is widely accepted, scheme 2.2. Little is known of the biosynthesis 
of the pyriminidine moiety in eukaryotes and it would appear that there 
are two competing pathways 102. Both pathways have been shown to utilize 
formate and a pentose. Recently Tazuya et al demonstrated the 
incorporation of the two ring nitrogens of histidine into the N-3 and amino 
nitrogen at the C-4 of the pyrimidine 103 indicating that at least in the 
major pathway the N-i, C-2 and N-3 of histidine are incorporated into the 










The thiazole unit originates from an amino acid, a five carbon sugar 
and a sulphur source. In yeast the precursors are glycine and a pentulose 
phosphate'04 , and in bacteria they are tyrosine and a deoxypentulsoe' 05 . 
The sulphur source is presumed to be cysteine although this has yet to be 
confirmed. 
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An outline of the proposed biosynthetic pathway for the synthesis of 
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(scheme 2.4) 
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The presence of tyrosine in the scheme was shown by a series of 
experiments with [U-14C] ,  [214C] and [15N] tyrosine in E. coli and 
Salmonella typhinurium showing that the C-2 and ring nitrogen of the 
thiazole moiety are derived from tyrosine'. White identified 4-
hydroxybenzyl alcohol as a metabolite of tyrosine in E. coli grown in the 
absence of thiamine or the thiazole'07 . 
Here again the intact incorporation of a 2C-N unit from 
tyrosine could be demonstrated using [2- 1 C, 15N] labelled tyrosine 
although the small amounts of thiamine produced in bacteria would 
negate the use of ninr for detection of the label. However mass 
spectroscopy has been used effectively to study the incorporation of stable 
isotopes into thiamine. 
Due to the commercial unavailability of a [2- 1 C, 15N]tyrosine and 
its obvious usefulness as a biosynthetic probe, we decided to investigate 
the possibility of synthesising such a probe. Routes to many labelled 
tyrosines have been reported in the literature and here we review a few of 
the more profitable routes. 
Many methods are available for the introduction of stable isotopes 
into the carboxy function of tyrosine. The two most widely reported are 
based on the Erlenmeyer azlactone synthesis and the Bucherer hydanthin 
synthesis. 
Introduction of the label via Erlenmeyers' classic synthesis 108 
(scheme 2.5) involves the preparation of hippuric acid from carboxy 
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labelled 	glycine 	followed 	by 	condensation 	with 	4- 
methoxy 6erzJdeJ 3de 	to form the oxazolone (35). Base hydrolysis of 
(35) yields the corresponding a-benzylamine acrylic acid and subsequent 
hydrogenolysis of the double bond followed by hydrolysis yields the 

































Although favoured for some time this approach has become less 
frequently used due to the high cost of the labelled starting material and 
the number of low yielding reactions involved. Yields reported for this 
route vary from 3-60% even for scaled up reactions 109 . 
The Bucherer hydantoin synthesis offers a more direct route to 
carboxy labelled tyrosine. This involves the reaction of the 4-
methoxyphenylacetaldehyde bisuiphite adduct with potassium cyanide 
and ammonium carbonate to produce the 4-methoxybenzylhydantoin 
which upon acid hydrolysis yields D,L-tyrosine (scheme 2.6). The 
attraction of this route lies in the label source of the the Cl atom being 
the inexpensive potassium cyanide and in the fact that there is only two 
steps to concern with. This route was first employed by Lotfield' 10 to 
produce [1- 14C]-D,L-tyrosine with a reported yield of 65% from the 
cyanide. However later workers have been unable to reproduce his 
yields"1 ' 109 . 
A third method of preparing carboxy labelled tyrosine has recently 
been reported using the Strecker route' 09. This involoves the reaction of 4-
methoxyphenylacetaldehyde with potassium cyanide and aqueous 
ammonia to produce the corresponding a-aminonitrile, scheme 2.7. 
Subsequent hydrolysis of the a-amino nitrile yielded the D,L-amino acid 
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Scheme 2.7 
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2.5.2-1N Labelled Tvrosine 
Two established routes exist for the synthesis of 15N-labelled 
tyrosine. The first is the standard Erlenmeyer synthesis using 15N-glycine 
as the label source" 2. The second is the reaction of either 15N-glutamic 
acid or 15N-aspartic acid with 4-hydroxyphenyl pyruvic acid mediated by 
the enzymes tyrosine amino transferase and aspartate amino transferase 
which gives a 55% yield of the final product with respect to the labelled 
precursor. This method was later improved by Baldwin et al who utilised 
15N aspartic acid, aspartate transaminase and 4-hydroxyphenylpyruvic 
acid to prepare 15N L-tyrosine in 80% yield 113  (scheme 2.8). This approach 
was also used in the synthesis of { 15N, 2- 13C]tyrosine using [2- 13C]-4-
hydroxyphenylpyruvic acid prepared via the base hydrolysis of the 
Erlenmeyer product (36) of [2- 13C]glycine (scheme 2.9) giving [2-
13C, 15N]tyrosine in a yield of 36% from [213  C]glycine"3 . 
0 









2.5.3 Side Chain Labelled Tvrosine 
The routes reported in the literature for the synthesis of ring and 3-
C labelled tyrosines include the previously mentioned Bucherer and 
Erlenmeyer routes. These involve the synthesis of a suitably labelled 
aldehyde, a phenylacetaldehyde or a benzaldehyde respectively 112"14 . 
A more commonly used route however is the alkylation of the 
sodium salt of 	either 	diethyl acetamidomalonate 	or ethyl 
acetamidocyanoacetate with an appropriately labelled 4-methoxybenzyl 
bromide"2"5. Hydrolysis of the alkylation product yields the 
appropriately labelled tyrosine, scheme 2.10. An example is the synthesis 
of [3',5'- 13 C2]tyrosine performed by Hruby which gave an overall yield of 
22% over ten steps" 5 . 
0 
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Scheme 2.10 R"= HOL 
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The body of literature outlining various routes to labelled tyrosines 
offers a few ideas for designing a viable route to [2- 13C, 15N]tyrosine. Here 
we discuss three attempts at formulating a synthesis of the required 
product. 
One of the most useful and general methods for the synthesis of 
amino acids is the alkylation of diethyl acetamidomalonate (37) with an 
alkyl halide, scheme 2.11. Several applications of this procedure have 
been well documented in the literature' l2,116,117 . 
In order to prepare [2- 13C, 15N]tyrosine using this methodology it is 
first necessary to prepare [2- 13C, 15N]diethyl acetamidomalonate. To test 
the viability ot this route for a labelled tyrosine synthesis (37) was 
prepared by the two step procedure shown in scheme. 2.12 118. Treatment of 
diethyl malonate (38) with sodium nitrite in the presence acetic acid 
produces the intermediate diethyl isonitrosomalonate (39) which was 
subsequently reduced and acylated to produce (37) in 65% yield. 
CO Et 	 CO2Et 	__  
HON=< 	 (37) 
CO2Et 	 CO2Et 
(38) 	 (39) 
scheme 2.12 
Alkylation of (37) was then attempted using 4-methoxybenzyl 
bromide (40) prepared by the method of Baldwin et a1112 . Generation of the 
sodium salt of (37) using sodium ethoxide followed by addition of the 
halide (40), scheme 2.13, gave after purification (41) in only 17% yield. It 
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had been noted in other experiments involving the alkylation of (37) using 
alkyihalides that better results were obtained using sodium hydride as 















-' (41) 	 OMe  
scheme 2.13 
At this stage it was felt that yields of 65% and 59% for the first two 
steps coupled with the expensive nature of one of the starting materials, 
d i e-Vk,/  CT malonate, did not justify this as a potential route to [2-




The reaction of an aldehyde or ketone with an amine and sodium 
cyanide produces an a-aminonitrile which can readily be hydrolysed to 
give the corresponding a-amino acid (scheme 2.14). This reaction known 
as the Strecker reaction, has been used extensively for the synthesis of 
both labelled 10920 and unlabelled 12' amino acids. While attempts to 
produce tyrosine by this route have not always been successful it was 
thought that this route may be useful for the synthesis of [2-
13C, 15N]tyrosine since the nitrogen label could be incorporated from the 




X  H 
HA t0 2H 
R H 
scheme 2.14 
The initial target thus became the development of a satisfctory 
route to a suitably protected [1- 13C] 4-hydroxyphenylacetaldehyde. Since 
benzyl ethers can readily be removed by hydrogenation, hydrolysis with 
strong acids or sodium ammonia reductjon' 22 we elected to prepare 4-
hydroxypenylacetaldehyde(42) as the synthon. The route adopted for the 
























scheme 2.15 	 BzO 
(42) 
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The nitrile (44) was prepared quantitatively from 4-
benzyloxybenzyl chloride (43) and sodium cyanide. Although acid 
hydrolysis of (44) failed to provide the acid (45) without extensive 
decomposition of the starting material, base hydrolysis progressed 
smoothly to give (45) in a 73% yield. 
It was originally planned to convert the acid to its ethyl ester (46) 
and reduce this to the corresponding alcohol (47). However conversion to 
the ester gave an unsatisfactory yield of 54%. Subsequent reduction of 
ester with lithium aluminium hydride (LAH) gave 4-benzyloxyphenethyl 
alcohol (47) in 73% yield; an overall yield of 40% for the two steps. 
Attempts to produce the ethyl ester directly from the nitrile by alcoholysis 
were unsuccesful. However direct reduction of the acid to the alcohol 
using an excess of LAH was successful giving a 73% yield of the the 
alcohol (47). 
Oxidation of (47) using chromium trioxide and pyridine gave 4-
benzyloxyphenylacetaldehyde (42) in 80% yield, 43% yield from the 
chloride (43). This route is therefore well suited to the preparation of [1-
13C]-4-benzyloxyphenylacetaldehyde, since the 13C label could be easily 
incorpoated using 13C sodium cyanide as the label source in the initial 
step. 
While being ideal for the preparation of [1- 13C] (42) this route was 
unsuitable for the production of the large amounts of (42) required for the 
optimisation of the Strecker reaction conditions. A more economical large 
scale route proved to be the esterification and etherification of 4-
hydroxyphenylacetic acid (48) with benzyl chloride and reduction of the 
benzyl ester (49) with LAH to give the alcohol 123 , scheme 2.16, in 53% 
yield from the acid (48). 
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It was decided to employ a modification of the Strecker procedure 
where the intermediate cyanohydrin is prepared and isolated before 
carrying out the amidation reaction (scheme 2.17). This methodology has 
been found to give greater yields than the classic one pot Strecker 
procedure 120 . 121 . 
RA
o HOCN H2NCN 
H NaCN R>H NH 4
C1 R>H 
scheme 2.17 
Preparation of the cyanohydrin (50) was accomplished using the 
method described by Pierson et a1121 . Thus treatment of the preformed 
sodium bisulphite addition product of the aldehyde with aqueous sodium 










OH 	 NH 
BzO 	 BzO 
(50) 	 (51) 
scheme 2.19 
Temperature Time Yield 
60°C 4 hours 40% 
70°C ihour 41% 
70°C + room temp. 30 mm. + 12 hours 39% 
Table 2.1 
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The conversion of a cyanohydrin to the corresponding a-
aminonitrile has generally been effected either by passing gaseous 
ammonia into a solution of the cyanohydrin or by the addition of 
concentrated ammonia solution to an aqueous solution of the 
cyanohydrin'°9 ' 121 . Since neither of these procedures are practical for a 
15N labelled synthesis some other reagent had to be used. Ammonium 
chloride dissolved in aqueous sodium hydroxide provides a convenient 
source of ammonium hydroxide solution from the readily availible 15N 
labelled precursor. 
Simple addition of an alkaline solution of ammonium chloride to an 
aqueous ethanol solution of the cyanohydrin gave after purification only a 
13% yield of the required product and in addition hydrolysis of the crude 
product with GN hydrochloric acid provided only a very small amount of 
impure material. This may be due to the initial insolubility of the 
cyanohydrin upon addition of the ammonia solution and subsequent 
decomposition of the unstable aminonitrile. 
Slow addition of the ammonia solution to the cyanohydrin (50) over 
a period of thirty minutes while maintaining the temperature at 60°C 
eradicated the insolubility problem and gave a 40% yield of the required 
product from the alcohol (47), scheme 2.19, which is higher than yields 
reported in the literature for similar reactions 110,124 . Attempts to optimise 
the reaction conditions by employing differing temperatures and reaction 
times did not significantly alter the yields obtained, table 2.1. 
Recently the application of ultrasound for increasing the intimacy 
of reagents in heterogeneous reaction systems has attracted increasing 
interest 125. However sonication of a suspension of the cyanohydrin in an 
aqueous ethanol solution of ammonium chloride and sodium hydroxide at 
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40°C gave only a 21% of (51). This represented a significant reduction in 
yield compared with that obtained using thermal agitation. 
An alternative method of obtaining a-aminonitriles from aldehydes 
described by Hanafusa et al using alumina as an inorganic support with, 
or without, ultrasonic irradiation has been reported to give increased 
yields compared with standard Strecker conditions'. For example 
phenyl-a-aminopropionitrile has been succesfully prepared. from 
benzylaldehyde, ammonium chloride and potassium cyanide in 64% yield 
in the abscence of ultrasonic radiation and in 90% yield with ultrasonic 
irradiation. 
4-Benzyloxyphenylacetaldehyde was heated in a suspension of 
potassium cyanide, ammonuim chloride and alumina in acetonitrile. This 
however provided only a multicomponent reaction mixture from which 
none of the required product could be isolated. Likewise treatment of the 
cyanohydrin (50) with ammonium chloride and alumina in acetonitrile 
also failed to produce any a-aminonitrile. 
Mai and PatillV have described a method for producing a number of 
a-amino nitriles from the corresponding trimethylsiloxynitriles and an 
amine in methanol solution : the siloxynitriles being prepared by the 
reaction of an aldehyde with trimethylsilyl cyanide in the presence of a 
catalytic amount of zinc iodide, scheme 2.20. 
The necessity to use methanol as the solvent for the amination 
reaction prevents the use of an inorganic ammonium salt as the mtogen 
source. However benzylamine should be a good source of the amine 
function in this reaction and this in turn should be easily prepared using 
the Gabriel method from benzyl chloride and potassium phthalimide' 28  
which is commercially available in the 15N labelled form. 
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4-Benzyloxyphenylacetalcjehyde (42) was converted to the 
trimethysilyloxy nitrile (52), a methanolic solution of benzylamine added 
and the solution heated under reflux. Fractionation of the reaction 
mixture gave a 27% yield of the 4-benzyloxypheny1aaminobenzy1.. 















Of the methods discussed here for the preparation of a-
aminonitriles from aldehydes it is clear that the alumina mediated 
reactions and the reaction via the trimethylsilyloxy nitrile are unsuitable 
for a synthesis of [2- 13C, 15N]tyrosine due to the low yields of the required 
products. However the modified Strecker reaction gives a 42% yield of the 
o<-amino-nitrile from the alcohol, over three steps, (corresponding to an 
average yield of 75% for each of the three steps). It was therefore decided 
to proceed with this route and to develop suitable conditions for the 
hydrolysis of (51) to D ,L-ty-rosine. 
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Attempts to produce tyrosine directly from the acid hydrolysis of 
(51) using cone. HC1, 9N HC1 or 48% HBr afforded only low yields of an 
impure product. Base hydrolysis using potassium hydroxide in an 
aqueous ethanol solution however produced O-benzyl-tyrosine (54) in 
excellent yield, scheme 2.22. Final deprotection of (54) was acccomplished 
using a mixture of trifluoroacetic acid and trifluoromethanesulphomc acid 
at O'C'29  to give D,L-tyrosine in 79% yield from (54), (17% yield from 4-
benzyloxybenzyl chloride). 
NH2 
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scheme 2.22 
2.6.3 Reductive Aminatign of 4-Hvdroxvithenyl2vruyjc Acid 
The route described by Baldwin et a1 99 for the synthesis of [2-
13C, 15N]tyrosine utilizing the Erlenmeyer intermediate prepared from 





















synthesis of this compound. The paper however offers no experimental 
details and although an overall yield of 36% is quoted the amount of 
tyrosine produced by this enzymatic method if not mentioned and it is 
likely that this route will only be useful in producing small amounts of 
labelled material. It would therefore be useful if another method of 
reductively aminating the pyruvic acid could be found. 
Sodium cyanoborohydride is a versatile reagent that can reduce a 
variety of functional groups with remarkable selectivity' 30. It has been 
observed that sodium cyanoborohydride will reduce an iminium ion much 
faster than a carbonyl group (scheme 2.23). 
It is thus possible to reductively aminate an aldehyde or ketone by 
simply reacting the carbonyl compound with an amine in the presence of 
sodium cyanoborohydride. The optimum pH for this reaction being 3-4. 
This methodology has been extended to the reductive amination of 
substituted pyruvic acids providing a new synthesis of a-amino acids. This 
is claimed to be the most efficient and economical route to 15N-labelled a-
amino acids and has been used to synthesis 15N-tryptophan (55) using 
ammonium nitrate as the amine source, scheme 2.24, giving a 23% yield 
of (55)131. 
To test the viability of this method as a route to 15N-tyrosine, 4-
hydroxyphenylpyruvic acid was reductively aminated, using the same 
procedure as described above for the tryptophan synthesis giving a 30% 
yield of tyrosine, scheme 2.25. The reaction was also carried out using 
ammonium bromide as the amine source which gave a more satisfactory 
yield of 90%. 
In order to utilize this approach for the synthesis of [2- 13C, 15N] 
tyrosine it was necessary to prepare [2-' 13C]-4-hydroxyphenylpyruvic acid 
(56). Baldwin et al synthesised (56) from the oxazolone (57) via base 
hydrolysis. However no experimental details are available and it was 
therefore necessary to repeat the synthesis to establish the optimum 
conditions. 
N-Benzoylglycine (58) was prepared from benzoylchloride and 
glycine in 93% yield using a method previously reported by Baldwin et 
aPe, scheme 2.26. The azlactone, 4-(4'-acetoxybenzylidene)- 2-3N-
oxazolin-5-one (57) was prepared from (58) under standard Erlenmeyer 
conditions giving (57) in 61% yield. Hydrolysis of the aziactone to produce 
4-hydroxyphenylpyruvjc acid however proved to be more difficult. 
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Unsaturated azlactones are converted to a-ketoacids by strong 
mineral acids or alkalies in either aqueous or alcoholic solutions. Alkaline 
hydrolysis has generally proven more effective'32. 
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Refluxing the aziactone (57) in 10% aqueous sodium hydroxide for 
one hour produced only the acylaminoacrylic acid (59) indicating the need 
to use more forcing conditions. Heating (57) in a 6.25M sodium hydroxide 
solution at 20°C, in a sealed reaction vessel, produced an intractible solid 
which could not be removed from the reaction vessel. 
Attempts to produce the pyruvic acid using acid hydrolysis 
produced a deep purple coloured solution from which none of the required 
product could be isolated. 
A more satisfactory procedure for the preparation of substituted 
pyruvic acids from aziactones has been reported 183 involving the base 
hydrolysis of the aziactone followed by saturation of the cooled reaction 
mixture with sulphur dioxide, allowing the removal of the benzoic acid 
bisuiphite addition product from which the aketo acid is regenerated 
using acid hydrolysis. 
The aziactone (57) was therefore heated in 10% sodium hydroxide 
solution at 100°C for rime hours. Saturation of the resulting solution with 
sulphur dioxide enabled the removal of the benzoic acid however upon 
heating the filtrate with hydrochloric acid to regenerate the a-keto acid a 
deep purple coloured solution was formed from which no product could be 
isolated 
In summary, of the three routes investigated here the one involving 
the modified Strecker reaction appears to be the most satisfactory. This 
should enable the production of enough [2- 13C, 15N]tyrosine to carry out 
the biosynthetic studies discussed earlier. 
Further work would have to be carried out on the third route in 






Fig. 3.1 Influenza virus particle. 
M. 
3.1 Introduction 
The influenza virus is a member of the family of negative strand 
RNA viruses known as myxo viruses (Gk. myxa meaning mucus). These 
are again subdivided into two groups: the orthomyxoviruses, or influenza 
viruses, and the paramyxoviruses or parainfluenza viruses which include 
mumps, measles, rubella and Newcastle disease viruses. 
A number of detailed monographs on the virology of the influenza 
viruses are available. The most informative of these oxe 61 FU 	KruS 
The influenza virus particle, or virion, has four main structural 
units, fig.3.1. These are:- 
The nucleocapsid, the core particle containing the genetic 
information, RNA polymerases and core structural proteins. 
The outer envelope, a lipoprotein membrane which is partially 
derived from the outer envelope of the host cell. 
Hemagglutimn (HA), the major surface glycoprotein which is 
involved in the initial stages of virus-host cell interaction. 
Neuraminidase (NA), the surface glycoprotein responsible for the 
removal of sialic acid groups from the host cell surface. 
Influenza viruses are divided into three types A, B and C based on 
their antigenic determinants. Influenza A is the principal cause of 
epidemic influenza while influenza B is usually associated with a milder 
disease, but can cause winter epidemics. Influenza C is not thought to be 
a human pathogen. 
The fact that the influenza virus continues to be an important 
human pathogen, frequently causing widespread disease and significant 
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loss of life is due to the extensive variation of the hemagglutinin and 
neuramimdase glycoproteins. Two types of variation have been noted. 
Antigenic drifts which result in minor antigenic changes causing isolated 
outbreaks known as epidemics, and antigenic shifts which result in major 
antigenic changes causing worldwide outbreaks known as pandemics. 
Antigenic drifts usually occur every one or two years while antigenic 
shifts occur at less frequent intervals. Both glycoproteins vary 
independently to produce variant viruses, but HA variation is considered 
more important because it is quantitatively the major surface glycoprotein 
and the antigen against which neutralising antibodies are directed. 
Pandemics this century have been associated with variations of the 
HA with or without variation of the NA. The 1918-1919 pandemic was 
particularly severe killing at least 20 million people world wide and was 
associated with a swinelike influenza virus termed H1N1, where Hi and 
Ni designate the antigenic description of the HA and NA glycoproteins. 
Since 1933, when the influenza virus was first isolated from 
humans two major antigenic shifts have occured; in 1957 the H2N2 
subtype, Asian influenza, replaced the H1N1 subtype and in 1968 the 
Hong Kong, H3N2, virus appeared. The reappearance of the H1N1, 
subtype in 1977 caused infection only in people under the age of twenty 
one indicating that older people had antibodies to the virus due to 
exposure before 1957. 
Since 1977 both H3N2 and H1N1 strains have co-circulated 
throughout the world with the ratio of H3 to Hi isolates changing 
dramatically from year to year and an underlying cyclical turnover of 
infection moving between the two strains'. 
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3.2 Influenza Virus Proteins 
The influenza virus comprises eight negative strand RNA 
segments, ten proteins and a plasma membrane. The plasma membrane is 
derived from the host cell while the genetic and protein components are 
synthesised in the infected host cell. 
The eight RNA segments code for the ten polypeptides. Three 
involved in transcription of the influenza virus, two surface proteins, two 
matrix proteins, two non-structural proteins and a structural protein 
associated with the nucleocapsid. This is summarised in table 3.1. 
RNA Segment Encoded Polypeptide Function 
P132 Component of 
transcription complex. 
2 PA Component of 
transcription complex. 
3 HA Major Surface 
Glycoprotein. 
4 NP Structural protein of 
the nucleocapsid. 
5 NA Surface glycoprotein. 
Ml Major component of 
virion underlying the 
M2 lipid bilayer. 










Fig. 3.2. Entry of the virus into the cell. 
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Since viruses do not possess the required synthetic machinery for 
self-reproduction they must enter the host cell to replicate. 
The attachment of the influenza virion to the host cell is mediated 
by the HA protein whose spikes interact with the sialic acid rich 
glycoprotein receptor of the host cell. Following binding the virion is 
transported into the cell via the endocytotic pathway. The virus particle 
becomes surrounded by a coated pit, a specialised region of the cell 
membrane where the cytoplasmic side of the membrane is coated with the 
protein clathrin. The coated pit then folds inwards and pinches off into 
the cytoplasm to form a "coated vesicle", the outer surface of which is now 
surrounded by clathrin. Inside the cell the vesicle loses its clathrin coat 
and fuses with an endosome. The.endosome-vesicle complex then merges 
with a lysosome. The interior of the lysosome is more acidic than other 
regions of the cell and this acidity is thought to cause the outer viral 
membrane to fuse with the membrane of the lysosome. The nucleocapsid 
is thus freed into the cytoplasm initiating infection 135"37, figure 3.2. 
Once within the cell the viral genome is transported to the nucleus 
where replication takes place. The mechanism by which this transport 
takes place is not known. The RNA of the virus itself is non-infectious. 
The mRNA's of the virion are transcribed by the virion associated RNA 
transcriptase. 
The transcription of the viral genome is the first event after entry 
(+) Strand RN, 
Progeny Virus 
(-) Strand RN 
I 
Virion Enzymes 
(-) Strand Parental RNA 	0 (+) mRNA 	No Proteins 
Fig. 3.3 Protein / RNA cycle. 
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to the cell. Replication of the viral genome then proceeds under the 
direction of the newly synthesised viral proteins. A full positive strand is 
made which serves as a template for the synthesis of negative strand 
genomic RNA's. Fig. 3.3 shows the translation-transcription cycle. 
The two modules that comprise the influenza virion are assembled 
in different locations : the nucleocapsid in the nucleus and the envelope at 
the cell surface membrane. 
Assembly of the nucleocapsid is the least well understood of the two 
assembly processes, however it must involve the transport of proteins 
from the cytoplasm to the nucleus where the ribonucleoprotein assembly 
takes place. 
The assembly of the viral envelope is better understood. In common 
with the other negative strand RNA viruses the last step in assembly of 
the influenza virus is associated with its egress from the cell'. 
The HA and NA glycoproteins become inserted into both the inner 
and outer surface of the plasma membrane. The NA glycoprotein is 
anchored to the membrane by an uncleaved signal-sequence near its N-
terminus forming tetrameric spikes at the cell surface. The HA 
glycoprotein is synthesised with a cleavable N-terminal signal peptide 
and is anchored in the membrane by a hydrophobic domain near its C-
terminus forming spike shaped trimers at the cell surface. 
The M2 protein is also an integral membrane protein that is 
expressed at the cell surface of infected cells with an extracellular domain 
of 18-28 amino acids. This along with the HA and NA glycoproteins 
constitutes the polypeptide fraction of the virion lipoprotein membrane. 
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The Ml protein is thought to underly the lipid bilayer and appears 
to serve the important role of bridging the gap between the nucleocapsid 
and the carboxy-terminal cytoplasmic domains of the glycoproteins which 
are already anchored into the nascent virus envelope patches. The Ml 
protein first associates with the membrane bound proteins and budding 
begins when the nucleocapsid diffuses to the membrane and begins to 
associate with the Ml protein. As more Ml proteins are bound the 
membrane of the cell is forced to curve around the nucleocapsid which 
finaly breaks off releasing the virus which is now free to renew the 









Fig. 3.4 Overview of the replication process. 
Fig. 3.5 The HA trimer. 
M. 
3.4 Hemat!idutinin 
The hemagglutinin glycoprotein of the influenza virus is the 
antigen against which neutralising antibodies are directed and is 
probably the most widely studied components of the influenza vinon. 
The three dimensional structure of the }{A molecule has been 
solved using X-ray crystallography' and sequencing has provided the - 
complete primary structure of a number of HA proteins allowing the 
functional domains and antigeni c regions to be interpreted' 40. The primary 
structure of the HA proteins reveal some important features. 
The amino terminus commences with a signal sequence of 15-16 
amino acids. The next region, approximately 550 amino acids long 
comprise, the HAl subunit (approximately 330 residues) and the }{A2 
subunit (approximately 220 residues). The HAl and HA2 subunits are 
linked by a single arginine residue which is cleaved after the formation of 
a stable tertiary structure. The two units remain closely associated after 
cleavage, held together not only' by non- covalent bonds but also by a 
disulphide bridge linking the N-terminus of the HAl with the HA2 
subunits. The HA molecule is anchored to the cell membrane at the 
carboxy terminus of the HA2 subunit by a stretch of hydrophobic residues 
which span the lipid bilayer. The remainder of the carboxy terminus, a 
region of approximately ten residues, protrudes into the cytoplasm. The 
polypeptide is heavily glycosylated at specific asparagine residues. 
The HA proteins form a glycoprotein spike on the cell surface, each 
spike being a trimer of HA molecules, figure 3.5. Each HA monomer forms 
an elongated structure consisting of a stalk capped with a large globular 
region at one end and a smaller globular region at the membrane end. , The 
HAl chain comprises the small globular region at the stalk and the entire 
65 
globular region while the HA2 chain is confined to the stalk and the 
smaller globular region at the membrane surface. 
The attachment sites for the cellular receptors are located on the 
top surfaces of the the large globular regions where the folding of the HAl 
chain creates small pockets to accomodate the sialic acid of the 
glycoprotein receptor of the host cell. The large globule also seems to 
contain all the sites involved in virus neutralisation. 
3.5 Protein Tarietini 
The targeting of proteins from their point of synthesis in the 
cytoplasm to their required destination within the cell has attracted much 
interest over the past few years 14 ' 
Eukaryotic cells, in contrast with prokaryotic cells, are subdivided 
into functionally distinct compartments, known as organelles, each of 
which is surrounded by one or more membranes. Each organelle contains 
its unique compliment of proteins enabling it to carry out specific 
functions within the cell. These proteins, generally synthesised in the 
cytoplasm, must be transported from this matrix into or through various 
membrane structures to reach their required destination. This raises one 
of the fundamental questions in cell biology, namely how are proteins 
made in one subcellular compartment accurately and efficiently 
transported to their final destination in another? 
Eukaryotic DNA is located mainly in the nucleus, although a small 
fraction is found in the mitochondria. The nuclear DNA encodes the 
majority of proteins within the cell. 
Protein synthesis in the nucleus begins with the transcription of 
nuclear DNA into messenger RNA (mRNA) which, after splicing, is - 
Fig. 3.6 Protein trafficing pathways. 
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transferred to the cytoplasm where it is translated into protein on 
ribosomes Hereafter the proteins must be directed to their appropriate 
intracellular locations. 
After synthesis on cytoplasmic ribosomes the fate of different 
proteins diverge : proteins bound for the endoplasmic reticulum (ER), 
Golgi apparatus, lysosome and extracellular locations enter the secretory 
or Palade pathway whereas those targetted to other intracellular 
organelles such as the nuclei, mitochondria or peroxisome are processed in 
a different manner. 
Targetted proteins not destined for the Palade pathway are 
transported directly from the cytoplasm by mechanisms that do not 
necessarily appear to be tied to translation. Delivery of proteins to the 
remaining membranes and organelles of the cell is initiated by transfer of 
the nascent polypeptide across the membrane of the endoplasmic 
reticulum by a process tightly coupled to translation; chain elongation and 
translocation across the membrane appearing to occur simultaneously. 
From the ER, proteins can be transported by the exocytotic or Palade 
pathway to various intracellular organelles or to the cell surface or 
exterior either continuously, "constitutive secretion" or as a result of 
stimulation by some extracellular agent, "regulated secretion". Thus in 
eukaryotic cells there are variety of different pathways for protein 
trafficing, fig. 3.6. There must therefore be some mechanism by which 
proteins destined for different organelles are specifically recognised and 
accurately transported. 
Some insight into the mechanisms by which such processes might 
operate was gained when in 1972 it was discovered that the 
immunoglobulin light chain protein was synthesised as a precursor that 
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was slightly larger than the secreted protein' 42 . 
Subsequently studies of this and other secretory proteins have 
shown that the extra material contained within the precursor proteins of 
targetted polypeptides consists of a polypeptide extension to the N-
terminal of the protein 143 ' 144 . It has now been shown that the N-terminal 
presequences contain the information necessary for the targeting of the 
proteins into the secretory pathway and the term "signal peptide" has 
been applied to the precursor extensions. 
Presequence peptides are also necessary for the targeting of 
endoplasmic reticular, nuclear, proxisomal, mitochondrial and chloroplast 
proteins of eukaryotic cells, and are also required for the secretion of 
secretory proteins in prokaryotic organisms. In prokaryotes the signal 
sequences are required to direct secretory and integral membrane proteins 
to and across the bacterial cytoplasmic membrane. 
There has been considerable interest in these signal peptides since 
their discovery, and while a considerable amount of knowledge has been 
gained about the characteristics of these sequences there is still little 
evidence as to the actual mechanism by which they mediate the 
translocation of large water soluble proteins across the hydrophobic 
environment of the phospholipid bilayer core. 
Viral glycoproteins are transported from their site of synthesis in 
the cytoplasm to the outer-membrane of the host cell utilizing the same 
machinery used for transport of host cell integral membrane proteins. It 
is now clear that a common pathway exists for the transport of proteins to 
the cell surface. This pathway is organised spatially and temporally as a 
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sequence of membrane bound compartments each containing its own 
compliment of processing enzymes. Movement through the exocytic 
pathway is vectorial, there is no evidence for a backflow of proteins. 
Proteins enter the pathway at the ER membrane and travel through the 
Golgi to reach the cell surface or secretory granules, lysosomes or 
vacuoles. 
The signal sequences of bacterial proteins targetted towards the 
bacterial secretory pathway have been found to be similar to those of 
eukaryotes and while comparison of ER and bacterial signal sequences 
show a low degree of sequence homology it also shows a number of 
common characteristicsl 45-151 . Analysis has revealed that signal sequences 
vary in length from 15-35 residues and are exclusively N.terminal 
although not always cleavable. Three structurally, and possibly 
functionally, distinct regions have been identified as the building blocks of 
a secretory presequence, fig. 3.7. 
CORE REGION 
	 CLEAVAGE SITE 
N-TERMINAL REGION 	 I C-TERMINAL REGION 
TURN INDUCING 
AMINO ACID 
Fig. 3.7 Structurally distinct regions of secretory signal sequences 
The N-terminal region can vary in length from 2-10 amino acids 
and usually contains at least one Lys or Arg residue and is positively 
charged. The second region, the core region, is essential in both pro- and 
eukaryotes. It consists of a stretch of nine or more residues containing 
hydrophobic or neutral residues and is predicted to form an a-helix. This 
region is usually terminated by a turn-inducing amino acid, proline or 
glycine. The final region, the C-terminal region precedes the signal 
peptidase cleavage site and consists of five to seven residues of higher 
polarity than those in the core region. Small apolar residues generally 
occupy the positions -1 and -3 (-1 being the position on the N-terminal 
side of the cleavage site) with position -2 usually occupied by an aromatic 
amino acid. 
The steps by which the nascent polypeptide is directed to and 
across the membrane of the ER occur rapidly and have therefore been 
difficult to analyse. Most of the information about this process has been 
derived from experiments performed in vitro in which translocation is at 
least an order of magnitude slower than in vivo. The precise relationship 
of these results to the situation in vivo is however unclear. However for 
proteins such as the HA protein which contain an N-terminal signal 
sequence the general sequence of events in the exocytic pathway appears 
to be as follows. 
As the nascent polypeptide chain emerges from the ribosome the 
hydrophobic signal sequence is recognised by a ribonucleoprotein complex 
called the signal recognition particle (SRP) 152153 . The 54 kDa component 
of the SRP is observed to bind to the hydrophobic portion of the signal 
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sequencelM.lSS, but only in the presence of ribosomes 158. Binding of the 
SRP to the signal sequence causes a pause in translation' 56"57"58 . 
Evidence suggests that there is only one type of SRP in a particular 
organism, and it follows that it must recognise different signal sequences. 
The signal recognition particle-ribosome complex then interacts 
with the SRP receptor (SRPR) or docking protein 156"57"58, a heteroclimeric 
complex consisting of a and 0 subunits. The 0 subunit is a peripheral 
membrane protein which can be anchored to the face of the ER via the - 
subunit'62"63". Sequencing of the oc-subunit' 62 has shown that it contains 
sequences similar to those in nucleic acid binding proteins and it is 
thought that it may bind to the 7S RNA component of the SRP. This 
provides a functional ribosome-membrane junction permitting 
translocation of the nascent peptide chain across the ER membrane. The 
SRP and SRPR are not constituents of the ribosome membrane junction 
and are likely to be recycled once they have accomplished the initial 
targetting' 58 . Attachment of the ribosome complex can however occur in 
the absence of the SRP and may involve binding to a signal sequence 
receptor on the ER membrane' 56 . 
The mammalian signal peptidase, responsible for cleavage of the 
signal sequence after translocation, has recently been purified as a 
complex of six polypeptides'56 , two of which are glycoproteins. It is 
postulated that only one subunit of the isolated complex carries out signal 
peptide cleavage, the other subunits performing some other related 
functions. The amount of this protein complex present in microsomes 
roughly equals the amount of bound ribosomes and it can be conjectured 
that the signal peptidase complex may also function in ribosome binding 
71 
or in some other aspect of translocation such as forming a pore through 
the membrane. 
It has been suggested that the movement of largely hydrophobic 
proteins through the lipid bilayer requires a protein pore' 65 . Alternatively, 
it has been argued on thermodynamic grounds that a loop of polypeptide 
may be able to pass through the membrane without the aid of accessory 
proteins'67 . One possibility is that the channel through the membrane 
could be formed by lipids in a non-bilayer formation with their hydrophilic 
headgroups lining the walls. The possibility that the signal peptides 
themselves could form the pore has been discounted' 65 . 
An alternative hypothesis is that a channel could be formed by a 
membrane protein, such as those co-purified with the mammalian signal 
peptidase'66, which would form the channel and fold around the secretory 
protein as it penetrates the membrane. While none of these putative 
"translocases" have been firmly identified a recent experiment carried out 
by Blobel et al using electrophysiological techniques has demonstrated the 
existence of a protein-conducting channel in the endoplasmic reticulum' 65 . 
Initial results indicate that the channel closes upon dissociation of the 
robosome from the membrane. This suggests that the ribosome may 
directly interact with part of the protein conducting channel. Further 
purification of the components linked with the import machinery may 
identify the channel forming proteins. 
Oligosaccharides are added to the HA polypeptide rapidly after 
specific asparagine residues are exposed in the lumen of the ER 170 . 
Glycosylation occurs by the transfer of a branched oligosacharide of the 
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structure GlcNAc2Man9Glc3 from the dolichol-lipid carrier to an 
asparagine of the tripeptide motif Asn.X.(Thr or Ser). 
In the ER trimming of the terminal glucose residues from the 
mannose rich oligosaccharide substituents occurs, followed by removal of 
a single mannose unit. This may occur either co-translationaly or post-
translationaly. Within the ER, proteins destined for transport represent 
only a fraction of a percent of the total protein content. The resident 
proteins of the ER do not cycle between the ER and the Golgi apparatus 
indicating the presence of a gate that functions to permit the transport of 
transient proteins to the Golgi while preventing the exit of the vastly more 
numerous ER resident proteins. The precise location of this gating 
function is not known although it is thought to occur before or during the 
sorting of the transient proteins into the transport vesicles that are 
responsible for moving exocytic proteins to the Golgi complex. 
Trimerisation of the HA protein begins in the ER and is complete 
by the time the protei a reaches the medial Golgi compartment. However it 
is not clear if trimerisation and folding of the HA is completed within the 
ER. The HA is then transported to the Golgi apparatus in small vesicles 
which move between the transitional elements of the two organelles. The 
protein travels through the Golgi complex where modifications to the 
oligosaccharide side chains take place. Upon exit from the Golgi the HA 
protein enters the trans-reticular network (TGN), a post Golgi 
compartment consisting of a tubular network of vesicles that appear to be 
continuous with the trans Golgi cisternae. The TGN initiates export of 
proteins to the cell surface in secretory granules. 
In epithelial cells, influenza glycoproteins are sorted within the cell 
and are displayed only at a particular domain of the plasma membrane. 
Epithelia are composed of polarized cells that maintain at least two 
distinct specialisations of their plasma membranes, the apical and 
basolateral domains'7 ' 
The glycoproteins of the influenza virus are recognised by epithelial 
cells as belonging to the apical class of surface molecules 172,173.  It is not 
clear what role, if any, these cells have in the infectious cycle of viruses, 
however it is worth noting that polarized epithelial cells of the upper 
respiratory tract are the primary site of influenza virus infection and 
release of viral proteins towards the apical or luminal surface favours the 
development of localized rather than systemic infection. 
3.10 Influenza Virus HA Si gnal Sequences 
As discussed above the signal sequence appears to contain all the 
information necessary for the targeting of proteins to the appropriate 
membrane. 
Numerous mutations of HA signal sequences have been constructed 
in order to elucidate their functional requirements' 70. Expression of HA 
cDNAs from which sequences encoding the signal peptide have been 
deleted results in the production of HA molecules that remain in the 
cytoplasm, demonstrating that the HA signal sequence is necessary for 
translocation. This is confirmed in experiments where sequences encoding 
the signal peptide region of the HA protein were fused to sequences 
encoding for proteins that normally do not cross the ER membrane. When 
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Fig. 3.8 Model for the insertion of ER signal sequences into membranes. 
(a) Association of the positively charged N-terminus with the lipid 
headgroups. (b) Insertion of the signal peptide into the membrane in a 
sheet like conformation. (c) The hydrophobic core region undergoes a 
conformational change to an a-helix, in the process forming a channel 
through which the translocation of the protein can occur. 
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preceded by an }{A sigani sequence both SV40 large TAg and a modified 
aminoglycoside 3' phosphotransferase II, proteins normally located in the 
nucleus and cytoplasm respectively were translocated into the ER and 
glycosylated. It has also been shown that the HA signal can be replaced by 
a heterologous signal sequence corresponding to some other exported 
protein without affecting transport, a finding consistent with the earlier 
observation that there is little of no amino acid conservation between 
signal peptides of HA's from different virus strains. 
Although the presence of the three structurally distinct regions 
within the signal sequences are necessary the precise structure-fimction 
relationship of specific residues are poorly understood. 
Various mechanisms for the interactions of the different types of 
targeting sequences with membranes have been formulated and these fall 
broadly into two groups' 74. One view postulates the existence of specific 
protein assemblies within the lipid bilayer, which are responsible for 
facilitating the motion of proteins across the membrane during protein 
synthesis. The second view assumes protein insertion to be a spontaneous 
process that does not require specific apparatus. However the concept that 
a crucial role is played by the structure of the secreted protein is central to 
both these models. 
While the structure formed by the signal peptide in a water filled 
protein channel could be influenced by signal peptide protein interactions, 
the structure of a signal peptide inserted into the lipid bilayer is expected 
to undergo folding in discrete stages. 
A model involving the insertion of signal peptides into the lipid 
bilayer has been suggested' 74 , fig. 3.8. The positively charged N-terminus 
of the signal peptide interacts with the lipid headgroups. This is followed 
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by the insertion of the signal peptide into the membrane in a 3-sheet like 
conformation. The hydrophobic core region of the signal peptide then 
undergoes a conformational change to an a-helix. As a result of the 
conformational change, a segment of the mature protein enters the 
membrane allowing translocation through the membrane to proceed. 
Some clarification of the mechanism of import to the ER could be 
achieved if some method of determining the structure of the signal 
sequence during the transport process were available. While such an 
undertaking is not feasible using techniques currently available an 
approach which is experimentally feasible is the determination of the 
structure of the signal sequence in the type of environment encountered 
by the peptide during import i.e. the hydrophobic lipid bilayer. The 
presence or absence of defined secondary structural features under these 
conditions might lend credence to the validity of the various mechanisms. 
Circular dichroism (CD) measures the optical activity of 
asymmetric molecules in solution based on the difference between the left 
and right handed components of circularly polarised light. 
Optical activity in peptides stems from two different forms of 
chirality. Asymmetry in the individual amino acids is the lesser 
contributor while architectural dissymmetry, for example the handedness 
of helices, has a major effect on the optical rotatory power of a peptide 
molecule. Since certain structural elements show strong characteristic 
spectra it is possible to draw conclusions from the optical rotation on 
conformation. 
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The far UV (amide) region of the CD spectra (170-250nm) is 
dominated by contributions from the peptide bonds whereas the near UV 
region contains contributions from aromatic regions and disulphide 
bridges. Structural information is therefore gained from the amide region 
of the spectra. The helix is the structural element showing the strongest 
CD spectrum. Such spectra are highly characteristic, showing a double 
minimum with the minima located at 200-206 and 222nm. The CD 
spectrum of a 3-sheet is relatively weak being dependant on the length 
and spatial arrangement of the strands and is characterised by a single 
minimum. Estimates of t3-sheet content in peptides and proteins from CD 
are considerably less reliable than those for a-helices. 
To examine the aspects of secondary structure that might be crucial 
• for the function of HA signal peptides it was decided to synthesise the 17 
residue peptide of the hemagglutinin protein from the influenza virus 
A/WSN/33 15  using solid phase peptide synthesis (SPPS). The primary 
structure of the signal peptide is shown in fig. 3.9. 
H.Met1 .Lys.Ala.Lys.Leu 5.Leu.Val.Leu.Leu. 
Tyr10.Ala.Phe.Val.Ala.Thrl 5 .Asp.Ala.OH 
Fig. 3.9 Presequence (1-17) of Hemagglutinin A/WSN/33. 
The methodology of solid phase peptide synthesis (SPPS) was first 
introduced by Merrifield in 1962 176.177 and involves the covalent 
attachment of the C-terminal amino acid in a sequence to an insoluble 
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support. Chain elongation then proceeds using methods similar to those 
developed for solution phase peptide synthesis. The major advantage of 
this approach is that separation of the reagents can be achieved by 
filtration allowing the resin-bound peptide to be thoroughly washed after 
each step to ensure complete removal of any soluble contaminants 178 . 
Recently methodology has been developed for the protection of the 
a-amino function with base labile protecting groups allowing the 
utilization of side chain protecting groups and resin linkers which are 
cleavable under milder conditions than the, very strong acid used with 
earlier protecting group stratges. In these syntheses an orthogonal 
approach is used with transient protection of the a-amino function 
normally achieved using the base labile 9-fluorenylmethoxycarbonyl 
(Fmoc) group developed by Carpino and Han' 79. This protects the a-amino 
function as a carbamic acid ester, which is easily cleaved to give the 
amine and dibenzofulvene via a 13-elimination mechanism by reaction 
with a base. If a secondary amine such as morpholine or piperidine is used 
the amine subsequently adds to the dibenzofulvene to yield a stable 
tertiary amine. Fig. 3.10 shows the deprotection using piperidine as the 
base. 
The insoluble resin support used with the Fmoc protection strategy 
is the p-alkoxybenzylalcohol resin developed by Wang' 80 from which the 
peptide can be cleaved using 50% trifluoroacetic acid (TFA). 
3.12.2 Activation of Amino Acids 
In order to convert carboxylic acids into acylating agents their 
hydroxyl group must be replaced by an electron-withdrawing group, thus 
augmenting the nucleophilic attack of the amino group. The standard 
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acylating agents are the symmetrical anhydride or an active ester of the 
amino acid. 
The symmetrical anhydrides are generated in situ by the reaction of 
the amino acid with diisopropylcarbodiimide (DIC). The amino acid reacts 
with the DIC to form an 0-acylisourea which then reacts with the carboxy 
component of excess unreacted amino acid to produce the anhydride. 
Although the symmetrical anhydride is formed rapidly and is very 
reactive, there are several side reactions associated with carbodiimide 
activation. In addition the symmetrical anhydride approach does not 
make efficient use of sometimes costly protected amino acids since two 
equivalents of the amino acid are required to generate one equivalent of 
the acylating agent. 
A second activation method, using active esters of amino acids, was 
first introduced to circumvent the side reactions experienced in the 
symmetrical anhydride procedure. Addition of the powerful auxiliary 
nucleophile, 1-hydroxybenzotriazole (HOBt), to the 0-acylisourea complex 
results in the direct formation of the HOBt ester. The excellent acylating 
properties of the HOBt active esters generated in this way led to the 
adoption of this strategy into SPPS as an activating agent in its own right. 
This method of activation has the added advantage of only requiring one 
equivalent of the amino acid to produce the acylating agent. 
The loading of the C-terminal amino acid onto the resin support is 
most conveniently carried out by the reaction of the resin with an excess 
of the symmetrical anhydride of the required amino acid generated in the 
presence of DIC and the base N,N-dimethyhminopyridine (DMAP). 
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3.12.3 MonitozinLr the Progress of Pertide Synthesis 
The number of chemical reactions required to synthesise even a 
small peptide necessitates that high yields are obtained in each step. The 
final purity of a synthetic peptide depends on the efficiency with which 
each residue is incorporated into the growing peptide chain. To be sure of 
obtaining high yields some form of continual monitoring must be carried 
out. 
The use of the Fmoc protecting group allows the direct 
spectrometric monitoring of SPPS since the UV spectra of the 
dibenzofulvene and dibenzofulvene-piperidine adduct generated upon 
deprotection of the Fmoc group are characteristic of conjugated systems, 
absorbing at 300nm, thus differentiating the soluble product of the 
deprotection reaction from the non-aromatic reagents which do not absorb 
at this wavelength. 
In the synthesis carried out here deprotection mixtures were 
pumped through a UV detector and the absorbance recorded at 300nm. 
Comparison of the areas under the peaks recorded for each coupling cycle 
allowed some quantitative measure of the efficiency of each step. 
3.12.4 The Synthesis and Purification of the A/WSNI33 HA Signal 
Sequence 
This signal sequence, fig. 3.9, consists mainly of hydrophobic 
residues containing aliphatic side chains and as a result simplifies the 
synthetic problem in that only a few of the residues require to be side 
chain protected. The use of the Fmoc group allowed the protection of the 
hydroxy functions of threonine and tyrosine as t-butyl (t-Bu) ethers. The 
Loading of first amino acid onto resin 
/ 
Cap unreacted amino groups 
Ac20 / pyridine / DMF 6mm. 
Removal of Fmoc protection 
\ 	 20% piperidine in DMF 
1 x 5mm, 2 x 3mm, 1 x 1mm 
\ 
Couple next amino acid 
(1) Fmoc-AA-OH (2mmol) + DIC (immol) 45mm 
(1) Fmoc-AA-OH (immol) + DIC (immol) + HOBT (lrnmol) 45mm 
Last amino acid 
Cleavage of Frnoc group 
i 
Cleavage of peptide from resin, and 
side chain deprotection 
Fig. 3.11 Synthetic procedure 
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b-amino group of lysine was protected with the Boc group and the 
aspartic acid was protected as its t-Bu ester's'. 
Peptide synthesis was carried out on a 0.5mmol scale using the 
Applied Biosystems 430A peptide synthesiser. 
The C-terminal alanine residue in the sequence was loaded onto the 
Wang resin as its symmetrical anhydride and the loading efficiency 
determined by removing and drying a sample of the resin. The dried 
sample was deprotected using 20% piperidine in DMF and the absorbance 
of the Fmoc piperidine adduct measured against a standard solution of 
20% piperidine in DMF. This allowed quantification of the Fmoc-protected 
amino acid present on the resin. 
Both the symmetrical anhydride and the HOBt active ester 
methods were used in tandem in a double couple cycle consisting of an 
initial coupling with the appropriate symmetrical anhydride followed by 
coupling with the HOBt active ester of the amino acid. .The overall 
synthetic strategy is outlined in fig. 3.11. 
Deprotection of the amino function was achieved by treatment of 
the resin bound peptide with a solution of 20% piperidine in DMF for 5 
minutes followed by washing of the resin. The UV absorbance of the 
combined filtrates recorded at 314nm was recorded. Most of the 
deprotection was accomplished with the first cycle however three more 
short base treatments were carried out to ensure total deprotection. The 
resin was then thoroughly washed before the double coupling cycle of the 
next residue. Permanent blocking of any unreacted amine groups was 
achieved by the acetylation with acetic anhydride. Theoretically the final 
product should contain no deletion peptides, only truncated acylated 
peptide sequences. 
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In this synthesis a significant decrease in coupling efficiency was 
noticed on addition of the third amino acid, Thr 15, this was possibly due to 
base catalyzed ring closure to produce the 2,5-diketopiperazine' 78, fig. 
3.12. The coupling efficiencies for cycles 4 to 6 fluctuated by only a few 
percent. However in cycle 7, the addition of Tyr 1O, the coupling efficiency 
appears to rise by 38%. A possibility is that deprotected Fmoc adducts 
from earlier deprotection reactions might have become non-covalently 
attached to the resin by it-it interactions and were then released from the 
resin by subsequent washing. The introduction of the tyrosine residue 
could result in displacement of these bound Fmoc groups through 
preferential non-covalent interaction of the tyrosine aromatic ring to the 
vinyl resin. The remaining coupling cycles were carried out without any 
major coupling failures. 
Resin cleavage and side chain deprotection of the peptide was 
accomplished with 95% TFA using ethylmethylsuiphide and ethane 
dithiol as scavengers. Concentration of the crude deprotection mixture 
and addition of ether gave a colourless precipitate which was collected by 
filtration and dried. The resulting solid was insoluble in acetic acid 
solutions and organic solvents such as methanol, methylene chloride, 
trifluoroethanol and acetone. 
Since it is conceivable that the insolubility could be due to the 
presence of scavengers inhibiting penetration of solvent into the solid a 
second deprotected mixture was filtered into a solution of ethyl acetate 
diethyl ether, 1:1. After a few minutes the peptide precipitated forming a 
cloudy suspension which became gelatinous on standing. The peptide was 
removed by centrifugation and the pellet was resuspended in the ethyl 
82 
acetate ether solution and centrifuged. This process was repeated several 
times to ensure total removal of the scavengers. 
In this case the peptide could be dissolved on addition of imi of 
water to a suspension of the pellet in glacial acetic acid. The volume of 
water was then increased to give a solution of the peptide in 30% acetic 
acid. Attempts to lower the acetic acid concentration by the addition of 
more water or methanol resulted in precipitation. 
Analytical reverse phase high performance liquid chromatography 
(HPLC) of the crude peptide on C18-silica under standard conditions 
(eluting with a gradient of water(0.1% TFA) to acetonitrile(0.1%TFA)) 
showed no elution of the peptide from the column. 
While the product gave a positive ninhydrin test both in solution 
and when applied to either polyacrylamide gels or paper it did not migrate 
either on electrofocusing polyacrylamide gels or on paper electrophoresis 
over a range of buffer pH's. - 
Paper electrophoresis of the hydrolysis product of the peptide 
indicated qualitatively the presence of all the constituent amino acids. 
The mass spectrum (positive ion FAB) of the material showed a parent ion 
at 1867.8, the expected mass being 1867.4. It was therefore clear that the 
desired product was present in the reaction mixture. It can be conjectured 
that the hydrophobic nature of the peptide results in the precipitation in 
buffered solutions. 
Further attempts at reverse phase HPLC using conditions which 
have been used for other peptides, i.e. various concentrations of H20, 
acetomtrile with 0.1%, with various column supports were unsuccessful. 
Size exclusion chromatography on Sephadex G25 eluting with 30% 
acetic acid proved to be a more satisfactory method of purification. 
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Although the peptide was eluted from the column the yields of recovered 
material were low. 
Two major problems have been encountered in devising a reversed-
phase separation of hydrophobic peptides. The first is their limited 
solubility in aqueous media. Secondly very hydrophobic peptides bind 
strongly to reversed phase matrices and require high concentrations of 
organic solvents for elution. Under these conditions, the peptides may not 
be soluble and can precipitate or may be irreversibly absorbed on the 
support. 
The study of signal peptides and other hydrophobic peptide species 
have commonly beeA thwarted by problems associated with their 
purification. It would also appear that these problems are particularly 
pertinant to the purification of PRE A/WSN/33 HA. Several groups 
however have had success in purifying hydrophobic peptides using more 
powerful solvent systems than the standard acetomtrile-water systems. 
For example Halverson et al used the solvent system H20;(95:5, 
acetomtrile trifluoroethanol), 0.1% TFA to purify the nine residue 
peptide (60) on a C4 reverse phase column'. The addition of 
trifluoroethanol was claimed to be responsible for acceptable recoveries of 
the peptide. Formic acid in high concentration is also an extremely potent 
solvent for hydrophobic peptides and proteins. Hakeshoven and Dernick 
have previously used a solvent system of 60% formic acid with a gradient 
of acetonitrile to separate water insoluble polio virus structural 
proteins 183. A different approach was taken by Shinnar and Kaiser who 
managed to purify a synthetic peptide corresponding to the leader peptide 
of the M13 coat protein with a gradient of 40-70% acetonitrile in 0.02M 
sodium phosphate buffer, pH2.7, containing 0.10M sodium perchlorate'8. 
Attempts to purify PRE A/WSN/33 HA using the above protocols 
were uniformly unsuccessful , no peptide material being eluted from the 
columns. Attempts at using ion exchange chromatography were likewise 
frustrated by the insolulllity of the peptide in aqueous solvents and its 
relative lack of polarity. Anion exchange chromatography eluting with 2% 
acetic acid gave a single peak shortly after injection, indicating that the 
peptide eluted in the void volume. Cation exchange chromatography gave 
similar results. 
A useful method of purifying hydrophobic peptides has been 
reported by Katakai and lizuka 1 . In this approach the peptide is 
repeatedly precipitated from 1,1,1,3,3,3 hexafluoroisopropanol (HFIP) 
with methanol. PRE AIWSN/33 HA was found to soluble in HFIP and 
while no precipitaion occurred upon addition of methanol, the addition of 
water to the HFIP solution initiated precipitation. The precipitate was 
collected and the process repeated several times. The dried product was 
fourI-6 k soluble in HFIP To date HFIP is the only solvent found which is 
capable of dissolving the peptide after drying. 
Fig. 3.13 shows the purification procedure adopted which can be 
summarised as follows. Washing of the crude deprotection product with 
ethyl acetate-ether followed by size exclusion chromatography on 
Sephadex G-25 and repeated precipitation from }IFIP with water. In 
common with Rosenblatt's description of using tic to follow the 
purification of some hydrophobic peptides tic of PRE A/WSN/33 HA was 
complicated by the properties of the peptide which failed to migrate from 
the origin and although providing no clear indication of the homogenaity 
of the peptide it did demonstrate the removal of migrating impurities'. 
Final purity of the peptide was confirmed by amino acid analysis. 
3.13.1 Secondary Structure Prediction 
As the native conformation of peptides and proteins is coded in its 
amino acid sequence many efforts have been made to predict protein 
secondary structure from sequence data. The most widely used approach 
is that developed by Chou and Fasman 17 which is base on a statistical 
survey of a number of proteins of known secondary structure to assign 
helix and a-sheet potentials to each amino acid. This allows the average 
conformational potential of helix and 3-sheet for a given sequence to be 
calculated. This method is based on the concept that a cluster of four 
residues with high helix forming potential in a group of six residues will 
initiate the formation of an a-helix. The helical segment will extend in 
both directions until a set of four residues with low helical potential, helix 
breakers, are encountered. Any segment with (Pa)>1.03 and (Pa)>{P) is 
predicted to be helical. (Pa) and (Pp) being the average conformational 
potential for helix and 13-sheet respectively. Similarly a cluster of four 
residues with high 13-sheet forming potential, 0-formers, in a stretch of five 
amino acids will initiate 13-sheet formation. The 13-sheet is then 
propagated in both directions as long as the sheet contains less than 30% 
of residues with low 13-sheet forming potential. Any segment with 
(P13)>1.05 and (P13)>(Pa) is predicted to be 13-sheet. 
Analysis of PRE A/WSNI33 HA by this method gives (Pa)=1.18 and 
(P13)= 1.10, indicating a slight preference for helix formation. The first four 
residues have strong helical forming tendencies and no group of of helix 
breaking residues is encountered in the sequence. Thus the peptide is 
predicted to form an a-helix. The core region of the peptide, Leu 5 to Ala14, 
Solution Extremity (nm) Molar Elipticity 
(degcm2mot 1) 
100% HFIP 202 -9,500 
10% HFIP-MeOH 215 -16,800 








50% HFIP-H20 214 -6,900 
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Fig. 3.14 CD spectrum of PRE AJWSN/33 HA in HFIP. 
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when considered separately is predicted to form a 13-sheet, {P(x)=1.16 and 
(P13) =1.3. 
3.13.2 Circular Dichroism 
The methods available for the estimation of a-helix and 13-sheet 
content of peptides and proteins from CD data generally fall into two 
categories. The first calculates the percentage helicity from the molar 
ellipticity of the peptide or protein at a specific wavelength' 88. This 
method however does not give any indication of the 13-sheet content. The 
CONTIN program based on the method of Provencher and Glockner' 89 
falls into the second category and uses a linear combination of CD spectra 
of reference compounds with known secondary structure for the direct 
analysis of the CD spectrum of a peptide or protein by curve fitting. This 
gives both the percentages of cc-helix and 13-sheet and by default the 
proportion of random coil. 
The conformation of the synthetic peptide was initially studied in 
aqueous and alcoholic solutions; water, methanol, n-butanol and 
trifluoroethanol which contained portions of }IFIP. The aqueous solution 
was used to approximate the cytosolic medium and the alcoholic solutions 
to approximate the lipophilic intramembrane environment. 
Fig. 3.14 shows the CD spectra of PRE AIWSN/33 HA in the very 
polar solvent HFIP. The peptide shows a spectrum with negative 
ellipticity, which is characteristic of a predominantely random structure, 
table 3.2. Calculations of secondary structure content, tabulated in tables 
3.3 and 3.4, are concurrent with this view. 
Solution Otical Activity at 
208nrn  
% Helix 
100% HFIP -6,700 9 
10% HFIP-MeOH -11,800 27 
10% HFIP-BuOH -22,900 65 
10% HFIP-TFE -16,700 44 
50% HFIP-H20 -6,000 7 
50% HFIP-0.6% SDS -21,600 61 
Table 3.3 Percentage alpha helix as calculated by the GF method. 
Solution j3-sheet a-helix 
100% HFIP 45% 9% 
10% HFIP-MeOH 100% 0% 
10% HFIP-BuOH 9% 91% 
10% HFIP-TFE 54% 46% 
50% HFIP-H20 75% 25% 
50% HFIP-0.6% SDS 42% 58% 
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Fig. 3.15 CD spectrum of PRE AJWSN/33 HA in 10% HFIP-MeOH 
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Fig. 3.18 CD spectrum of PRE AIWSN/33 HA in 50% HFIP-H20 
A change in CD profile was observed in moving to the less polar 
solvent system, 10%HFIP-methanol, fig. 3.15. Here the spectrum has a 
single negative extreme at 215nm, [0] 215=-16,800degcm2dmol4 , indicative 
of a predominantely 13 structure, calculated as 91% 13-sheet by the 
CONTIN program. In the more lipophilic solvent mixture, 10%HFIP-n-
butanol the CD spectrum, fig. 3.16, shows two negative extremes, at 
208nm and 220nni, [6]=-22,900degcm2dmol-1 and [9]=-
19,000degcm2dmol-1 , characteristic of a predominantely helical 
conformation. The helical content was calculated as 65% using the 
Greenfield-Fasman (GF) method and 91% using the CONTIN program. 
The CD spectrum obtained of the peptide in 50%HFIP-water, fig. 3.17, has 
a single trough at 214nm, [6] 214=-6,900degcm2dmol-1 . This is again 
characteristic of a predominantely 13 structure, 75% as calculated by the 
CONTIN program with a low helical content, (35% from the CONTIN 
program and 7% as calculated by the GF method). In 10%HFIP-TFE a 
spectrum characteristic of a predominantely helical structure is obtained, 
fig. 3.18, with two negative extremes one at 207-208nm and one at 215nm, 
[O]=- 16,700degcm2dmol-1 and 101215=-15 ,400degcm2dmol-1 . Analysis 
using the CONTIN program showed almost equal amounts of a-helix and 
13-sheet (46% and 54% respectively). The GF method gave a helical content 
of 44%. 
These results indicate the formation of a predominantely helical 
structure in homogeneous lipophilic media, where hydrogen bonding to 
solvent molecules is not possible, and a predominantely 13-sheet 
conformation in more polar solvents. 
Detergent micelles are proposed to mimic an amphiphilic surface 






Fig. 3.19 CD spectrum of PRE A/WSN RAin 50% HFIP-0.6% SDS 
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A/WSN/33 HA peptide in 50%HFIP:aqueous sodium dodecyl sulphate 
(SDS) solution. This shows negative extremes at 207-208nm and 220nm, 
[0]2=-21,600 degcm2dmol-1 and [0]=-16,900degcm2dmol-1 , indicating a 
predominance of helical structure which contrasts with the 
predominantely [3-structure found in 50%HFIP:water. The CONTIN 
program gave a helical content of 58% with a [3-sheet content of 42% 
reversing the slight predominance of [3-sheet structure observed in the 
HFIP:H20 solution. A slightly higher value for the helical content of this 
system of 61% was obtained using the GF method which gives results 
comparable to the helical content found for the n-butanol solution. 
The series of CD studies therefore indicates an increased tendency 
to form an a-helical structure as the lipophilicity of the system increases 
whether by using more lipophilic alcohols as solvents or upon the addition 
of detergent micelles. These results would appear to support a model in 
which the transmembrane passage of the proteins is mediated in some 
way by the conformational transition of the hydrophobic sequences to a-
helices in the lipophilic environment of the membrane. 
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4.1 General Methods 
All starting materials were purchased from commercial sources 
mainly Aldrich, Lancaster and Fluka. Reagents were routinely distilled or 
recrystallized before use. All amino acids used for solid phase peptide 
synthesis were purchased from Novabiochem and used as suppplied. The 
following solvents were dried, using the reagents quoted in parenthesis, 
before distillation : diethyl ether, tetrahydrofuran (lithium aluminium 
hydride); acetone, methylene chloride (calcium chloride); ethanol 
(magnesium sulphate). 
Merck Kieselgel 100 silica was used for flash column 
chromatography. Thin layer chromatography (tic) was carried out on 
aluminium sheets precoated with Merck Kieseigel 60 silica. Solvent 
systems, for tic were either ethyl acetate/hexane (1:3) or n-butanol/acetic 
acid/water (13:2:5) unless otherwise stated. Visualisation of the 
components was achieved by either : iodine vapour, UV absorption at 
254nm or phosphomolybdic acid spray. Compounds with free amino 
groups were visualized with ninhydrin spray. 
High performance liquid chromatography was carried out using an 
Applied Biosystems system comprising 2 x 1406A solvent delivery system, 
a 1480A injector/mixer, and a 1783A detector/controller. The eluent was 
monitored at 277nm. Gel electrophoresis was carried out using the LKB 
Pharmacia PhastGel electrophoresis system. Amino acid analysis was 
carried out on an LKB 4150 alpha amino analyser following sealed tube 
hydrolysis in constant boiling hydrochloric acid at 100°C. 
91 
Infra red spectra were' recorded on a Perkin Elmer 781 
spectrophotometer using the polystyrene 1603cm 1 peak as a standard. 
Samples were tested as chloroform solutions. 
Electron impact (El) mass spectra were recorded on an AEI MS90Z 
or Kraths MS50TC spectrometer. Fast atom bombardment (FAB) spectra 
were recorded on a Kratos MS50TC spectrometer. 
Proton magnetic resonance spectra were recorded on either a Jeol 
JNM-PMX60 (60 MHz), Bruker WH360 (360 MHz) or Varian VXR5000 
(600MHz) spectrometer in the solvent indicated using tetramethylsilane 
(TMS) (5 0.0) as an external standard. 
Melting points were recorded on an electrically heated Reichard 
7905 melting point apparatus and are uncorrected. 
'JPI4ii:z. . PJt 	!T' fl Ff71 
Nmr experiments were performed on a Varian VXR-5000 
spectrometer at 600MHz or on a Bruker WH360 at 360MHZ. The 
experiments were carried out on a 5.2mM solution of the peptide in dmso 
d6. Data sets consisting of 256 t1 increments of 16 transients were 
collected for the ROESY experiment, with a mixing time of 200ms. The 
spectra were resolution enhanced by zero filling and sine bell 
multiplication. 
Data sets consisting of 256 t1 increments of 32 transients were 
collected for the COSY experiment and the spectrum processed as 
described for the ROESY spectrum. 
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4.3 Tvrosine Synthesis 
Diethyl acetamido-4'methoxvbenzvl-malonate (41) 
Diethyl acetamidomalonate (1.10g, 5mmol), prepared by the 
method of Zambito and Howe 118, was added to a solution of sodium (0.11g, 
5mmol) in ethanol (30cm 3) and the solution heated under reflux for thirty 
minutes. 4-Methoxybenzyl bromide (1.0g, 5mmol), freshly prepared by the 
method of Baldwin et al,112 was added and the mixture heated under 
reflux for 17 hours. The reaction mixture was allowed to cool to room 
temperature and the solvent removed under vacuum. The residue was 
crystallized from aqueous ethanol before purifying by flash column 
chromatography on silica gel eluting with 10% ethyl acetate in toluene. 
Recrystallization of the product from aqueous ethanol gave the required 
product (0.279g. 17%). mp 97-99°C (lit., 96-97°C) 190 . oH (CDCI3, 60MHz) 
1.57 (6H, t, 2xO2CH2CH3, J=7Hz), 2.13 (3H, s, CH3CO2), 3.72 (2H, s, 
CH20), 3.90 (3H, s, CH30), 4.40 (4H, q, 2xCO2CH2CH3, J=7Hz) 6.90 (2H, 
d, C6H4, J=8Hz), 7.08 (2H, d, C6H4, J=8Hz). ElMS mJz 337 (M, 4), 121 
(100), 43 (22), 40 (61), 32 (74%). 
Sodium hydride (0.24g, lOmmol) was added to a solution of 
diethyl acetamidomalonate (2.17g, lOmmol) in THF (25cm 3) and the 
solution heated under reflux for thirty minutes. 4-Methoxybenzyl bromide 
(2.4g, 12mmol) was added and the mixture heated under reflux for 16 
hours. The reaction mixture was allowed to cool to room temperature 
before filtering and evaporating to give a white solid which was purified 
by flash column chromatography on silica gel, eluting with 15% ethyl 
acetate in toluene. Recrystallization of the product from aqueous ethanol 
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gave the required product as white plates which were identical by nmr, 
tic, mass spec and mp to an authentic sample (1.46g, 43%). 
4-Benzyloxybenzyl chloride (2.00g, 8.6mmol), sodium cyanide 
(0.64g, 12.8mmol) and sodium iodide (100mg) were heated under reflux in 
acetone (20cm 3) for eight hours with the exclusion of moisture. The 
reaction mixture was cooled and filtered and the solid washed with 
acetone (50cm 3) and toluene (50cm 3). The combined acetone extracts were 
evaporated to dryness and the residue taken up in toluene (50cm 3). The 
toluene extracts were combined before washing with water (100cm 3) and 
drying over sodium sulphate. Evaporation gave a yellow oil which 
crystallized on standing, recrystallization from ethanol gave the nitrile 
(1.90g, 100%). mp 66-67°C. 8H (CDC13 60MHz) 3.64 (2H, s, ArCH2CN), 
5.10 (2H, s, ArCH20), 6.92 (2H, d, C6H4, J=8Hz), 7.24 (2H, d, C6H4 0  
J=8Hz), 7.36 (5H, s, ArH). ElMS mJz 223 (M, 24), 91 (100), 65 (25). 
m/z(EI) 233.0994 (M, C1 5H13N0 requires 223.0997). (Found: C, 80.3; H, 
5.88; N, 6.04. C15H13N0 requires C, 80.69, H, 5.87; N, 6.27%) 
Attemnted Synthesis of 4-Benzvioxyrhenv1acetic acid (45) 
4-Benzyloxybenzyl nitrile (0.5g, 2.4mmol) was suspended in 
10M sulphuric acid (20cm3) and heated under reflux for fifteen minutes. 
After cooling to room temperature the reaction mixture was extracted with 
ethyl acetate (100cm 3). Tic showed the reaction mixture to be 
multicomponent. No product was isolated from this reaction. 
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4-Benzyloxybenzylnitrile (2.00g, 8.97mmol) was dissolved in hot 
ethanol (40cm3). A solution of potassium hydroxide (7.5g) in water 
(15cm3) was added and the mixture was heated under reflux for 15 hours. 
The reaction mixture was diluted with water (100cm 3) and acidified to 
pHi with 6N HC1 before extracting with ethyl acetate (200cm 3). The 
combined extracts were washed with iN HC1 (200cm 3), dried over 
magnesium sulphate and evaporated to dryness to give an off white solid 
which was recrystallized from benzene to give the acid (1.57g, 73%). mp 
117-119°C. 8H (CDC13 , 601MHz) 3.60 (2H, s, ArCH2CO2H), 5.10 (2H, s, 
ArCH20), 6.97 (2H, d, C6H4, J=8Hz), 7.27 (2H, d, C6H4, J=8Hz), 7.36 (5H, 
s, ArH), 10.32 (1H, bs, CO2H). ElMS m/z 242 (Mt, 20), 91 (100), 65 
(13%). mlz(EI) 242.0937 (Mt, C15H1403 requires 223.0942). 
Attemoted Synthesis of Ethyl 4-benzvloxvohenvlacetic acid (46) 
4-Benzyloxybenzyl mtrile (0.5g, 2.4mmol) was taken up in a 
mixture of ethanol (15cm 3) and DMF (10cm3). Concentrated sulphuric 
acid (10cm3) was added and the mixture heated under reflux for fifteen 
hours. The reaction mixture was allowed to cool to room temperature and 
diluted with ice cold water (35cm3) before extracting with ethyl acetate 
(100cm3). The organic extract was washed with water (100cm 3) and 
evaporation gave an oil which crystallized on standing. Tic showed the 
product to be multicomponent. No product was isolated from this reaction. 
Ethyl 4-benzvloxvnhenvlacetic acid (46) 
4-Benzy1oxyphenylacetic acid (0.5g, 2.Ommol) was dissolved in a 
solution of ethanol (28.5cm 3) containing acetylchloride (2.5cm 3) and the 
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mixture stirred at room temperature for three hours. The reaction mixture 
was then concentrated to approximately 15cm 3 and made basic by the 
addition of aqueous sodium hydroxide before extracting with ethyl 
acetate. Evaporation gave the ester (0.29g, 54%). 6H (CDC13 , 60MHz) 1.23 
(3H, t, OCH2CH3 , J=8Hz), 3.55 (2H, s, ArCH2CO2Et), 4.17 (2H, q, 
OCH2CH3 , J=8Hz), 5.05 (2H, s, ArCH20), 6.93 (2H, d, C6H4, J=8Hz), 
7.23 (2H, d, C6H4, J=8Hz), 7.42 (5H, s, ArH). ElMS m/z 270 (M, 14), 
91(100%). 
4-Hydroxyphenylacetic acid (10.0g. 66mmol), benzyl chloride 
(19.8g, 156mmol), sodium iodide (10.8g), and potassium carbonate (21.6g) 
were stirred as a partial suspension in refluxing acetomtrile (200cm 3) for 
30 hours. The reaction mixture was filtered and the residue washed with 
acetomtrile (100cm3). The combined solutions were evaporated in uacuo 
and the residue recrystallized from aqueous ethanol to give the ester as a 
white solid (14.9g, 69%). mp 73-75°C (lit., 73-74°C) 1 . SH (CDC13 60MHz) 
3.60 (2H, s, ArCH2CO2), 5.05 (2H, s, ArCH20), 5.13 (2H, s, CO2CH2) 6.93 
(2H, d, C6H4, J=8Hz), 7.23 (2H, d, C6H4, J=8Hz ), 7.33 (5H, s, ArH), 7.40 
(5H, s, ArH). ElMS m/z 332 (M, 14), 91 (100), 65 (4). 
A. 4-Benzyloxyphenylacetic acid (2.0g, 8mmol) in tetrahydrofuran 
(50cm3) was added dropwise to a suspension of lithium aluminium 
hydride (1.1g, 27.5mmol) in tetrahydrofuran (50cm 3) with stirring. The 
resulting solution was stirred under reflux for 2 hours. The reaction 
mixture was allowed to cool to room temperature before adding water 
(2.2cm3), 15% sodium hydroxide (2.2cm3) and water (3.3cm 3). The mixture 
was filtered and dried over magnesium sulphate before evaporating to 
dryness to give an off white solid. Purification by flash column 
chromatography on silica gel gave a white solid which recrystallized from 
hexane as white plates (1.38g, 73%). m.p. 85°C (lit., 83-85°C) 1 . 
öH(CDC13, 60MHz), 1.43 (1H, s, OH), 2.80 (2H, t, ArCH2C, J=GHz), 3.83 
(2H, t, CH20H, J=6Hz), 5.07 (2H, s, ArCH20), 6.93 (211, d, C6H 4, J=8Hz), 
7.20 (2H, d, C 6H4, J=8Hz), 7.43 (5H, s, ArH). ElMS mJz 228 (M, 24), 91 
(100), 65 (10). (Found: C, 78.9; H, 7.12; N, 0.00. C1 5H1602 requires C, 
78.92; H, 7.06; N, 0.00%) 
Ethyl 4-benzyloxyphenylacetate (0.40g,1.5mmol) in THF (5cm3) 
was added dropwise to a suspension of lithium aluminium hydride 
(0.114g, 3.Ommol) in THF (40cm3) and heated under reflux for one hour. 
The reaction mixture was allowed to cool to room temperature before 
adding water (0.28cm 3), 15% sodium hydroxide (0.28cm 3) and water 
(0.69cm3). The suspension was filtered and the cake washed with ether. 
The resulting solution was dried and evaporation gave a white solid which 
was purified by flash column chromatography on silica gel eluting with 
ethyl acetate and hexane. This gave the required product as a white 
crystaline solid which was recrystallized from hexane as white plates 
(0.25g, 75%) which were identical by nmr, mp and tic to an authentic 
sample. 
Benzyl 4-benzyloxyphenylacetate (4.50g, 13.4mmol) in T}IF 
(50cm3) was added dropwise to a suspension of lithium aluminium 
hydride (1.20g, 31.6mmol) in THF (100cm 3). This was stirred under reflux 
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for 2 hours. The reaction mixture was allowed to cool to room temperature 
before adding enough saturated aqueous sodium potassium tartrate to 
produce a granular suspension. The solution was then filtered and the 
solid washed with THF. Drying over magnesium sulphate and removal of 
solvent gave an off white solid. Purification by flash column 
chromatography on silica gel and recrystallization from hexane gave the 
alcohol as white plates (2.31g, 75%), which were identical in m.p., tic and 
nmr to an authentic sample. 
Chromium trioxide (1.3g, 13mmol) was added to a stirred solution 
of pyridine (2.3cm3) in dry methylene chloride (40cm 3). This was stirred 
on an ice bath for five minutes and then at room temperature for a further 
ten minutes. 4-Benzyloxyphenethylalcohol (0.5g, 2.2mmol) in 
dichioromethane (5cm3) was added dropwise and stirring continued for 
three hours. The supernatant was decanted and the residue washed with 
ether (200cm3). The combined organic extracts were filtered through a 
celite pad and washed with 5% sodium hydroxide (200cm 3), iN HC1 
(200cm3), 5% sodium carbonate (200cm 3) and brine (200cm 3). Drying over 
magnesium sulphate and evaporating to dryness gave a clear oil (0.40g, 
80%). 5H (CDC13 , 60MHz) 3.55 (2H, d, CH2CHO, J=3Hz), 5.00 (2H, s, 
CH20), 6.92 (2H, d, C6H4, J=8Hz), 7.16 (2H,. d, C6H4, J=8Hz), 7.36 (5H, s, 
ArH ), 7.72 (1H, t, CHO). v max (CHC13) 2720 (CHO), 1718 (carbonyl), 
1605cm 1 ' (aromatic). 
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To a stirred suspension of 4-benzyloxyphenylacetaldehyde (191mg, 
0.85mniol) in water (3cm 3) was added a solution of sodium metabisuiphite 
(115mg, 0.6mmol) in water (3cm3) and stirring continued for one hour. A 
solution of sodium cyanide (115mg, 4minol) in water (3cm 3) was then 
added dropwise with stirring and stirring continued for a further three 
hours. The reaction mixture was extracted with ether (100cm 3) and the 
combined ether extracts washed with brine (100cm 3) and sodium 
metabisuiphite solution (100cm 3). Drying and evaporation gave the 
cyanohydrin (172mg, 80%) which was used directly in the next reaction. 
3H(CDC13, 60MHz) , 2.10 (1H, s, OH), 3.13 (d, 2H, ArCH2C, J=6Hz), 4.70 
(1H, t, CH, J=6Hz), 5.07 (2H, s, ArCH20), 6.07 (2H, d, C6H4, J=8Hz), 7.30 
(2H, d, C6H4, J=8Hz), 7.50 (5H, s, ArH ). Dm (CHC13) 3420 (OH), 2720 
(CN), 1605cm 1 (aromatic). 
A. 4-Benzyloxyphenyl-a-hydroxy-propionitrile prepared from 4-
benzyloxyphenethytlalcohol (500mg, 2.2mmol) was taken up in ethanol: 
water ,1:1, (30cm3) and treated with a solution of ammonium chloride 
(400mg,7.5mmol) in 2N potassium hydroxide (1.5cm 3) and heated at 50°C 
for 24 hours. The reaction mixture was allowed to cool to room 
temperature before evaporating in vacio top give a yellow oil, which was 
resuspended in ether, filtered and dried. Subsequent evaporation gave a 
yellow oil which was purified by flash column chromatography on silica 
gel eluting with 20% ethyl acetate in hexane (230cm 3) and ethyl acetate 
(70cm3) to give the aminonitrile (70mg, 13%) attemts to crystallize the 
product were unsuccessful. 8H (CDC13 60MHz) 1.70 (2H, bs, NH2), 2.98 
(2H, d, CH2, J=6Hz), 3.91 (1H, t, CH, J=6Hz), 5.10 (2H, s, ArCH20), 6.95 
(2H, d, C6H4, J=9Hz), 7.30 (2H, d, C6H4, J=9Hz), 7.43 (5H, s, ArH). ElMS 
mlz 225 (M-HCN, 17), 197 (7), 134 (51), 91(100%). umax (CHC13) 3400 
(NH2), 2210 (CN), 1605cnr1 (aromatic). 
4-Benzyloxyphenyl-cz-hydroxy-propionitrile prepared from 4-
benzyloxyphenethylalcohol (180mg, 0.79mmol) was taken up in ethanol 
(3cm3) and water (1cm 3) was added. The solution was slowly heated to 
60°C before a solution of ammonium chloride (120mg, 2.2nunol) in 2N 
sodium hydroxide (1cm 3) was added dropwise via a syringe over a period 
of fifteen minutes. Heating was then continued at 60°C for a further four 
hours. The reaction mixture was allowed to cool to room temperature and 
extracted with ether (20cm3). The aqueous layer was saturated with 
sodium chloride and reextracted with ether (20cm 3). The combined 
organic extracts were dried and evaporation gave a yellow solid, which 
was purified by flash column chromatography on silica gel eluting with 
50% ethyl acetate in hexane (100cm3) and ethyl acetate (100cm 3) to give a 
yellow solid (79mg, 40%) which was nmr and tic identical to an authentic 
sample. 
4-Benzyloxyphenyl-a-hydroxy-propionitrile prepared from 4-
benzyloxyphenethylalcohol (180mg, 0.79mmol) was taken up in ethanol 
(2cm3) and the solution diluted with water (2cm 3). A solution of 
ammonium chloride (250mg, 4.7mmol) in 10% sodium hydroxide (1cm 3) 
was added dropwise to the stirred solution over a period of 30 minutes 
maintaing the temperature of the solution at 70°C. Heating was continued 
at 70°C for 1 hour before allowing the solution to cool to room 
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temperature. The crude reaction mixture was extracted with ether 
(120cm3) and the combined organic extracts washed with water (100cm 3). 
Evaporation gave a yellow oil which was purified by flash column 
chromatography on silica gel eluting with a gradient of 0-100% ethyl 
acetate in hexane (100cm 3) and ethyl acetate (100cm 3) to give the 
aminonitrile (82mg, 41%), which was tic and nmr identical to an authentic 
sample. 
4-Benzyloxyphenyl-cz-hydroxy-propiomtrile prepared from 4-
benzyloxyphenethylalcohol (180mg, 0.78mniol) was taken up in ether 
(4cm3). This was added to a solution of solution of water and ethanol, 1:1 
(4cm3) which was maintained at a temperature of 70°C at a rate which 
allowed the ether to evaoporate off slowly. A solution of ammonium 
chloride (55mg, 1.0mmol) in 2N sodium hydroxide (1cm 3) was added 
dropwise via syringe over a period of thirty minutes. The temperature was 
reduced to 30°C and stirring continued for a further 12 hours. The 
reaction mixture was allowed to cool to room temperature before 
evaporated to dryness and resuspending in ether. Filtration and 
evaporation gave a yellow solid, which was purified by flash column 
chromatography on silica gel eluting with 20% ethyl acetate in hexane 
(150cm3) and ethyl acetate (100cm 3) to give a yellow solid (72mg, 39%) 
which was nmr and tic identical to an authentic sample. 
4-Benzyloxyphenyl-a-hydroxy-propiomtrile prepared from 4-
benzyloxyphenethylalcohol (1.0g, 4.4mmol) was taken up in hot ethanol 
(20cm3) and diluted with water (10cm 3). The solution was slowly heated 
to 70°C and a solution of ammonium chloride (700mg, 13mmol) in 10% 
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sodium hydroxide (2.5cm3) added dropwise via syringe over a period of 
twenty minutes. The mixture was stirred at 70°C for a further ninety 
minutes before cooling to room temperature and extracted with ether 
(75cm3) and the ether extract washed with water (200cm 3) before drying 
and evaporating to give a yellow oil, which was purified by flash column 
chromatography on silica gel eluting with 50% ethyl acetate in hexane 
(100cm3) and ethyl acetate (100cm 3) to give a yellow solid (213mg, 27%) 
which was nmr and tic identical to an authentic sample. 
4-Benzyloxyphenyi-a-hydroxy-propionitrile prepared from 4-
benzyloxyphenethylalcohol (500mg, 2.2mmol) was taken up in ethanol 
(7cm3) and the solution diluted with water (7cm 3). To the resulting 
suspension was added ammonium chloride (500mg, 9.3mmol) in 10% 
sodium hydroxide (5cm3). This was somcated at 40°C for 6 hours. The 
reaction mixture was extracted with ether (300cm 3) and evaporated to 
give a yellow oil which was purified by flash column chromatography on 
silica gel eluting with hexane (30cm3), 50% ethyl acetate in hexane 
(80cm3) and ethyl acetate (60cm 3) to give the aminomtrile (91mg, 21%), 
which was tic and nmr identical to an authentic sample. 
4-Benzyloxyphenyiacetaldehyde 	prepared 	from 	4- 
benzyloxyphenethylalcohoi (180mg, 0.78mmol) was taken up in 
acetonitrile (5cm 3) and added to a stirred suspension of ammonium 
chloride (130mg, 2.4mmol) potassium cyanide (130mg, 2.Ommol) and 
alumina (500mg) in acetomtrile (15cm 3). The suspension was heated, with 
stirring, at 50°C for 24 hours. The reaction mixture was allowed to cool to 
room temperature before filtering and evaporating to give a yellow oil, 
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which was resuspended in ether, filtered and dried. Subsequent 
evaporation gave a yellow oil which was found to be multicomponent by 
tic. No product was isolated from this experiment. 
H. 4-Benzyloxyphenyl-a-hydroxy-propionitrile prepared from 4-
benzy1oxyphenethylalcohol (100mg) was taken up in acetonitrile (15cm 3). 
Ammonium chloride (130mg, 2.4mmol) and alumina (500mg) were added 
and the suspension heated at 50°C for 24 hours. The crude reaction 
mixture was filtered and the filtrate dried and evaporated to give a yellow 
oil which was multicomponent by tic. No product was isolated from this 
reaction. 
4-Benzyloxyphenylacetaldehyde 	prepared 	from 	4- 
benzyloxyphenethylalcohol (500mg, 2.2mmol) was taken up in 
dichloromethane (5cm3) and zinc iodide (10mg) added. 
Trimethylsilylcyarnde (0.30cm3, 2.2mmol) was added to the stirred 
solution under argon with cooling. Stirring was then continued at room 
temperature for fortyfive minutes. A solution of benzylamine (0.24cm 3, 
2.2mmol) in methanol (5cm 3) was added and the resulting solution heated 
under reflux for two hours under argon. The reaction mixture was cooled 
to room temperature before evaporating to dryness. The residue was 
taken up in ether and dried before filtering and evaporating to give a 
yellow oil which was purified by flash column chromatography on silica 
gel eluting with a gradient of 0-60% ethyl acetate in hexane (200cm3) to 
give an off white solid which was crystallized from ethanol giving the 
aminonitrile (193mg, 27%). mp 115°C. 8H (CDC13 , 60MHz) 1.70 (2H, bs, 
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NH2), 2.98 (2H, d, CH2, J=6Hz), 3.91 (1H, t, CH, J=6Hz), 5.10 (2H, s, 
ArCH20), 6.95 (2H, d, C6H4, J=9Hz), 7.30 (2H, d, C6H 4, J=9Hz), 7.39 (5H, 
s, ArH), 7.43 (5H, s, ArH). ElMS m\z 315 (M-HCN, 12), 224 (10), 198 
(13), 91(100%). FABMS m\ z+ 343 (Mi-H), 316, 226, 197, 91. umax (CHC13) 
3310 (NH), 2210 (CN) 1610cm 1 (aromatic). 
4-Benzyloxyphenyl-a-amino-propiomtrile (74mg, 0 .29mmol) was 
suspended in 48% hydrobromic acid (5cm 3) and the sealed tube heated at 
100°C for 16 hours. The resulting dark brown solution was evaporated to 
dryness and taken up in water (5cm 3). The suspension was filtered 
through a plug of charcoal to give a clear solution which was 
multicomponent by tic. Purification by cation exchange chromatography 
on Dowex AG50W X8 eluting with a gradient of 0-1M pyridine in water 
provided no pure tyrosine by tic. 
4-Benzyloxyphenyl-a-amino-propiomtrile (50mg, 0.20mmol) was 
suspended in concentrated hydrochloric acid (5cm 3). The resulting 
suspension was treated as above and provided no pure tyrosine by tic. 
4-Benzyloxyphenyl-cz-amino-propionitrile (50mg, 0.20mmol) was 
suspended in 6N hydrochloric acid (5cm 3) before heating and 
chromatographing as above. Tic of the ninhydrrn positive fractions showed 
no pure tyrosine. 
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4-Benzyloxyphenyl-a-amino-propionitrile (55mg, 0 .22mmol) was 
taken up in ethanol (20cm 3) before adding a solution of potassium 
hydroxide (3.7g) in water (7.5cm 3). The solution was stirred at 100°C for 
five hours and cooled to room temperature. The ethanol was removed by 
evaporation and the aqueous neutralised with 6N HC1. The solution was 
filtered and filtrate applied to a column of Dowex AG50W X8 ion exchange 
resin and eluted with water (500cm 3) and iN ammonium hydroxide 
(300cm3). The ninhydrin positive fractions were pooled and dried to give 
the required product as a white solid which was tic and nmr identical to 
an authentic sample (59mg, 100%). 
4-Benzyloxyphenyl-a-hydroxy-propiomtrile prepared from 4-
benzyloxyphenethytlalcohol (180mg, 0.79mmol) was taken up in ether 
(3cm3) and added to a solution of ethanol:water, 1:1, (3cm 3). This was 
slowly added to a heated reaction vessel at 50°C allowing the ether to 
evaporate. Ammonium chloride (130mg, 2.4mmol) in 2N sodium hydroxide 
(0.5cm3) was added with stirring and heated at 50°C for 2 hours before 
cooling to room temperature and stirring for three days. The reaction 
mixture was evaporated to dryness and taken up in ether before filtering. 
The ether solution was added to 9N HCI (4cm3) and heated gently 
allowing the ether to evaporate. The reaction vessel was then sealed and 
and heated at 110°C for 14 hours. The cooled reaction mixture was 
evaporated to dryness and the residue taken up in water (4cm 3). The 
aqueous solution was adjusted to pH7 and applied to AG50W X8 Dowex. 
Elution with a gradient of 0-1M pyridine in water gave mnhydrin positive 
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fractions which were pooled and freeze dried to give a white solid which 
was multicomponent by tic. 
O-Benzyl-D,L-tyrosine (50mg, 0.20mmol) was treated with 
thioarnsole (1.2cm3), trifluoromethanesulphonic acid (0.1cm 3) and TFA 
(2cm3) for 30 minutes at 0°C. The mixture was concentrated in vacuo to 
give an oil which wastaken up in water (3cm3) and neutralised with 10% 
NaOH dofore applying to a column of Dowex AG50W X8 and eluting with 
water (500cm3) and iN ammonium hydroxide (300cm3). The mnhydrin 
positive fractions were pooled and freeze dried to give a white solid (34mg, 
79%) which comigrated with an authentic sample of L-tyrosine on tic. 
.V4i rn(-) 	 'AIJ F1i1s) xI(,Ta'1 
N-benzoylglycine prepared by the method of Baldwin et al' (2.21g, 
12.2mmol), sodium acetate (2.21g, 26.9mmol), acetic anhydride (8.3cm 3) 
and 4-acetoxybenzaldehyde (4.3g, 3.68cm3, 26.3mmol) were heated at 
100C for 2.5 hours with stirring. The reaction mixture was then cooled 
and treated with ethanol (11cm 3). The resulting suspension was stirred 
for 15 minutes before standing at room temperature for 14 hours. The 
precipitate was collected and washed with cold ethanol (50cm 3) and hot 
water (50cm3). The solid was dried under vacuum to give a yellow solid 
(2.28g, 61%). mp 181-182°C (lit 180-181°C) 190. 8H (CDC13) 2.16 (3H, s, 
CH3CO2), 7.00-8.16 (10H, m, ArH, CH). umax (CHCI3) 1800, 1760 
(carbonyl), 1660cm 1 (C=N) . ElMS m\z 265 (M-AcOH, 5), 105 (100) 
77(19%). 
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Attemnted synthesis of 4-hvdroxvohenvhwruvic acid 
4-(4'-Acetoxybenzylidene)-3N-oxazolin-5-one (500mg, 1.6mmol) 
was suspended in 10% NaOH (30cm3) and heated at 100°C for 1.5 hours. 
The reaction mixture was cooled to room temperature and acidified with 
conc. HCI. The resulting precipitate was collected and washed with 2N 
HC1 before drying to give 2-benzamido-3-(4'-hydroxyphenyl)-prop-2-enoic 
acid (270mg, 95%). mp >210°C. 6H (dmso d6) 6.63-8.00 (10H, m, ArH, 
CH), 9.75 (1H, s, CO2H), 9.23 (1H, bs, NH). ElMS m\z 283 (M, 13), 239 
(6), 105 (100), 77 (36), 44 (11), 40 (21%). 
4-(4'-Acetoxybenzylidene)-3N-oxazolin-5-one (500mg, 1 .6mmol) 
was suspended in 6.25M sodium hydroxide (1.5cm 3) and heatedat 210°C 
in a sealed tube for 15 minutes. The resulting solution was cooled to room 
temperature, the resulting glass coluld not be removed from the reaction 
vessel. 
4-(4'-Acethxybenzylidene)-3N-oxazolin-5-one (3.0g. 9.8mmol) was 
suspended in a mixture of acetic acid (130cm 3) and 6N HC1 (37cm3) and 
heated at 100°C for 4 hours. The resulting deep purple solution was stored 
at 5°C overnight. No product separated on cooling. 
4-(4'-Acetoxybenzylidene)-3N-oxazolin-5-one (491mg, 1 .6mmol) 
was suspended in 10% sodium hydroxide (60cm 3) and heated at 100°C for 
9 hours. The resulting solution was cooled to room temperature and 
saturated with sulphur dioxide. The gelatinous solution was cooled to 
room temperature filtered and the filtrate acidified with cone. HC1. The 
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resulting solution was heated on a water bath for 4 hours giving a deep 
purple coloured solution. No product separtated on cooling. 
D.L-Tvrosine 
Sodiumcyanoborohydride (200mg, 3.2mxnol) was added to a 
soltion of 4-hydroxyphenylpruvic acid (180mg, 1.0mmol) and ammonium 
nitrate (100mg, 1.2mmol) in methanol (15cm3). The solution was adjusted 
to pH7.2 with 10% potassium hydroxide and stirred at room temperature 
for 60 hours. Concentrated hydrochloric acid (5cm3) was added and 
stirring continued for a further hour. The reaction mixture was 
evaporated to dryness and taken up in water. The slution was adjusted to 
pH7 and applied to AG50W X8 Dowex. Elution with water (500cm 3) and 
iN ammonium hydroxide (300cm3) gave mnhydrin positive fractions 
which were pooled and freeze dried to give a white solid (54mg, 30%). The 
product was identical by tic and nmr to an authentic sample. 
Sodiumcyanoborohydride (200mg, 3.2rnmol) was added to a 
solution of 4-hydroxyphenylpruvic acid (180mg, immol) and ammonium 
bromide (200mg, 2.Ommol) in methanol (15cm3). The solution was 
adjusted to pH7.2 with 10% potassium hydroxide and stirred at room 
temperature for 4 days. Concentrated hydrochloric acid (5cm 3) was added 
and stirring continued for a further hour. The reaction mixture was 
worked up as with the above reaction to give a white powder (162mg, 
90%) which comigrated with authentic tyrosine on tic. 
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N(a)-Fluorenylmethoxycarbonylalanine (1.46g, 4.6mmol) was 
dissolved in a minimum amount of dry DMF and diisopropylcarbodiimide 
(0.36cm3, 0.3g, 2.34mmol) was added before stirring at room temperature 
for five minutes. 
The resin (0.78nunolg4, 1.0g, 0.78mmol) was swollen in a minmum 
amount of DMF and a few crystals of DMAP added before somcating for 
five minutes. The Fmoc-Ala-OHIDIC solution was added to the resin and 
the mixture sonicated for three hours. The resin was filterd and washed 
with dry DMF and methylene chloride before drying. 
The loading of the amino acid on the resin was determined by 
suspending a sample of the resin in a solution of piperidine in DMF (20% 
v/v). The suspension was then somcated at room temperature for 15 
minutes. A UV spectrum of the solution was then obtained and the 
absorbance of the solution at 300nm measured. Comparison of this value 
against standard values obtained from the protected amino acids allowed 
the evaluation of the resin substitution which was found to be 82%. 
Fmoc-peptide-resin (0.5mmol) was treated with acetic anhydride 
(0.10g, 1.0mmol) and pyridine (0.080g, 1.0mmol) in DMF (7cm 3). The 
mixture was shaken for 2.5 minutes then filtered and treated with a 
further identical portion of acetic anhydride and pyridine in DMF. After 
MrA 
shaking for a further 3.5 minutes the mixture was filtered and the resin 
washed thoroughly with DMF. 
Fmoc-peptide-resin (0.5mmol) was treated with four portions of 
20% piperidine in DMF (9.0cm3) and shaken for 5, 3, 3 and 1 minute 
respectively. The mixture was filtered prior to each addition and the UV 
absorbance of the filtrate measured at 300nm on each occasion. After the 
last treatment the peptide-resin was washed thoroughly with DMF. 
Fmoc-amino acid (2.Ominol) was dissolved in DMF and treated 
with 0.5M DIC in DMF (2.0cm3, 1.0mmol). The solution was allowed to 
stand for 15 minutes. 
Fmoc-amino acid (1.0mmol) was dissolved in DMF (4.Ocm3) and 
treated with 0.5M DIC in DMF (2.0cm 3, 1.0mmol) and 0.5M 1-
hydroxybenzotriazole (HOBt) in DMF (2.0cm 3, 1.Ommol). The solution 
was allowed to stend for 15 minutes. 
The Fmoc-amino acids were coupled using procedure A, then 
recoupled using procedure B. 
The activated amino acid solution, from 4.4.4 A or B, was added to 
the peptide resin (0.5mmol). The mixture was shaken for 30 minutes then 
filtered and the resin washed thoroughly with DMF. 
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All peptides were assembled using an Applied Biosystems 430A 
peptide synthesiser. The synthesis was carried out on a 0.5mmol scale 
steps 4.4.2 to 4.4.5 inclusive ("capping", "deprotection", "activation" and 
"coupling") comprise the coupling cycle used to elongate the resin-bound 
peptide by one residue. Once all the amino acids had been coupled, one 
further round of capping and deprotection gives the free N-terminus. 
The following Fmoc-amino acids were incorporated with the side 
chain protection given in parenthesis : aspartic acid, threonine, tyrosine 
(t-Bu); lysine (Boc). The remaining amino acids were used unprotected. 
The resin bound peptide (100mg) was stirred as a suspension in 
a 1:1 mixture of ethyl methyl sulphide and ethaneclithiol (0.5cm 3) for 10 
minutes. Trifluoroacetic acid 95% (10cm3) was added and stirring 
continued for a further 3 hours under argon. The mixture was filtered and 
the filtrate concentrated to approximately 1cm 3 in vacuo. Addition of ice 
cold diethyl ether (10cm 3) gave an off white precipitate which was 
collected by filtration. The product was washed with ether (50cm 3) and 
dried. The solid was not soluble in water, glacial acetic acid, 50% acetic 
acid, dichloromethane or TFE. 
A portion of the resin bound peptide (100mg) was deprotected as 
above. The reaction mixture was filtered into a 1:1 mixture of diethyl 
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ether and ethyl acetate (50cm 3). The resulting suspension was centrifuged 
at 2000rpm for 10 minutes and the supernatant decanted. The solid was 
resuspended in a further portion of the above solvent and centrifugation 
repeated and the supernatant again decanted. This procedure was 
repeated a further five times to ensure removal of scavengers. The moist 
peptide was directly suspended in glacial acetic acid (9cm 3) and water 
added to give a solution of the peptide in 90% acetic acid. Dropwise 
addition of water gave a solution of the peptide in 30% acetic acid. 
Further addition of water resulted in precipitation of the peptide. 
The solution of the peptide in 30% acetic acid was applied to a 
column of G-25 Sephadex (2.5 x 30cm) and eluted with 30% acetic acid at 
25cm3 per hour. UV absorbance of the eluant was monitored at 254 and 
277nm. The appropriate fractions were pooled and lyophilised to give a 
white solid (10mg). The product was taken up in HFIP (1cm3) and 
addition of water (3cm3) resulted in precipitation of the product. The 
peptide was collected by centrifugation and resuspended in HFIP (1cm 3). 
Precipitation was repeated six times by this method. The peptide was then 
dissolved in HFIP (2cm 3). 30% Acetic acid (5cm3) was added and the HFIP 
removed in a stream of argon. Freeze drying gave peptide as a white solid 
(3mg). TIc using the solvent system pyridine:n-butanol:acetic acid:water, 
(10:15:3:12), showed removal of migrating impurities in during the course 
of the purification. FAB-MS m/z 1867.8, (C89,H147,N19,0S1 requires 
1867.4) Amino acid analysis: Asx1 (0.81), Thr1 (0.91), Ala4 (3.51), Va12 
(2.12), Met 1 (0.88), Leu4 (3.57), Tyr j (0.89), Phe1 (0.91), Lys2 (2.10). 
iW 
HPLC of PRE AJWSN/33 HA was attempted using the following 
solvent systems on both a C-8 and C-4 reversed phase column. 
A. 	Solvent A, acetomtrile (0.1% TFA). Solvent B, water (0.1% TFA) 
10 to 100% solvent A in solvent B over 30 minutes. 
100% solvent B for 10 minutes. 
B. 	Solvent A, acetonitrile (0.1% TFA). Solvent B, water (0.1% TFA) 
50 to 100% solvent A in solvent B over 30 minutes. 
100% solvent B for 10 minutes. 
C. 	Solvent A, ( 95:5 acetonitrile:TFE, (0.1% TFA)). Solvent B, water 
(0.1% TFA) 
10% solvent A in solvent B. 
10 to 20% solvent A in solvent B over 5 minutes. 
20 to 90% solvent A in solvent B over 15 minutes. 
90% solvent A in solvent B for 5 minutes. 
D. 	Solvent A, ( 95:5 acetonitrile:TFE, (0.1% TFA)). Solvent B, water. 
50 to 100% solvent A in solvent B over 30 minutes. 
100% solvent B for 10 minutes. 
E. 	Solvent A, acetomtrile. Solvent B 0.02M sodium phosphate buffer 
pH 2.7 containing 0. 10M sodium perchlorate. 
40 to 70% solvent A in solvent B over 30 minutes. 
70% solvent B for ten minutes. 
F. 	Solvent A, acetonitrile. Solvent B 0.02M sodium phosphate buffer 
pH 2.7 containing 0. 10M sodium perchiorate. 
50 to 100% solvent A in solvent B over 30 minutes. 
100% solvent B for ten minutes. 
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G. 	Solvent A, 40% acetonitrile in 60% aqueous formic acid. Solvent B, 
60% aqueous formic acid. 
10 to 60% solvent A in solvent B over 30 minutes. 
60% solvent B for 5 minutes. 
Ion exchange chromatography was carried out on using Whatman 
Partisil-10/25 SAX anion exchange and Partisil-10/25 SCX cation 
exchange columns with isochratic elution using 2% acetic acid and 0.1M 
ammonium acetate respectively. 
The above systems proved totally unsuitable for the purification of 
PRE A/WSN/33 HA with no product being eluted from the column. 
4.4. 11 Circular Dichroism (CD) 
Far UV CD spectra were recorded on a JASCO J600 
Spectrophotometer in the region 260-190nm using a quartz cell of path 
length 0.1mm at 27°C The data are presented as molar ellipticities. The 
spectra were analysed using the method of Greenfield and Fasman 188 and 
by the CONTIN program 189. 
A solution of the PRE A/WSN/33 HA was prepared by dissolving 
the peptide (1mg) in HFIP (1cm3). A series of CD spectra were recoreded 
in a variety of alcoholic and aqueous solutions such that the concentration 
of the peptide was 0.10 mgml'. 1.20cm 3 of each of the following solutions 
were used for each spectrum. 
A. HFIP 100%. 
 10% HFIP in methanol. 
 10% HFIP in butanol. 
 10%HFIPinTFE. 
 50% HFIP in water. 
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F. 	50% HFIP in 0.6% SDS. 
Results. 
Solution GF helix Contin helix Contin sheet 
A 9% 9% 45% 
B 27% 0% 100% 
C 65% 91% 9% 
D 44% 46% 54% 
E 7% 25% 75% 
F 61% 58% 42% 
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